+

US20160193026A1 - Pliable silk medical device - Google Patents

Pliable silk medical device Download PDF

Info

Publication number
US20160193026A1
US20160193026A1 US15/066,876 US201615066876A US2016193026A1 US 20160193026 A1 US20160193026 A1 US 20160193026A1 US 201615066876 A US201615066876 A US 201615066876A US 2016193026 A1 US2016193026 A1 US 2016193026A1
Authority
US
United States
Prior art keywords
silk
yarn
mesh
knit
pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US15/066,876
Inventor
Enrico Mortarino
Jessica L. Akers
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Inc
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2009/063717 external-priority patent/WO2010074827A2/en
Priority claimed from US13/156,283 external-priority patent/US20120004723A1/en
Priority claimed from US13/186,151 external-priority patent/US20120022646A1/en
Priority claimed from US13/306,325 external-priority patent/US20120185041A1/en
Priority claimed from US13/715,872 external-priority patent/US20130317526A1/en
Application filed by Allergan Inc filed Critical Allergan Inc
Priority to US15/066,876 priority Critical patent/US20160193026A1/en
Assigned to ALLERGAN, INC. reassignment ALLERGAN, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: AKERS, Jessica, MORTARINO, ENRICO
Publication of US20160193026A1 publication Critical patent/US20160193026A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/0063Implantable repair or support meshes, e.g. hernia meshes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/12Mammary prostheses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/36Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix
    • A61L27/3604Materials for grafts or prostheses or for coating grafts or prostheses containing ingredients of undetermined constitution or reaction products thereof, e.g. transplant tissue, natural bone, extracellular matrix characterised by the human or animal origin of the biological material, e.g. hair, fascia, fish scales, silk, shellac, pericardium, pleura, renal tissue, amniotic membrane, parenchymal tissue, fetal tissue, muscle tissue, fat tissue, enamel
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/005Ingredients of undetermined constitution or reaction products thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/148Materials at least partially resorbable by the body
    • DTEXTILES; PAPER
    • D04BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
    • D04BKNITTING
    • D04B1/00Weft knitting processes for the production of fabrics or articles not dependent on the use of particular machines; Fabrics or articles defined by such processes
    • D04B1/14Other fabrics or articles characterised primarily by the use of particular thread materials
    • DTEXTILES; PAPER
    • D04BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
    • D04BKNITTING
    • D04B21/00Warp knitting processes for the production of fabrics or articles not dependent on the use of particular machines; Fabrics or articles defined by such processes
    • D04B21/10Open-work fabrics
    • D04B21/12Open-work fabrics characterised by thread material
    • DTEXTILES; PAPER
    • D04BRAIDING; LACE-MAKING; KNITTING; TRIMMINGS; NON-WOVEN FABRICS
    • D04BKNITTING
    • D04B9/00Circular knitting machines with independently-movable needles
    • D04B9/10Circular knitting machines with independently-movable needles with two needle cylinders for purl work or for Links-Links loop formation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/0063Implantable repair or support meshes, e.g. hernia meshes
    • A61F2002/0068Implantable repair or support meshes, e.g. hernia meshes having a special mesh pattern
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2210/00Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2210/0004Particular material properties of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof bioabsorbable
    • DTEXTILES; PAPER
    • D10INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
    • D10BINDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
    • D10B2211/00Protein-based fibres, e.g. animal fibres
    • D10B2211/01Natural animal fibres, e.g. keratin fibres
    • D10B2211/04Silk
    • DTEXTILES; PAPER
    • D10INDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
    • D10BINDEXING SCHEME ASSOCIATED WITH SUBLASSES OF SECTION D, RELATING TO TEXTILES
    • D10B2509/00Medical; Hygiene
    • D10B2509/08Hernia repair mesh

Definitions

  • the present invention is a biodegradable (synonymously bioresorbable), biocompatible, pliable, knitted silk matrix, mesh or scaffold (the “device”) and methods for making and using the device in surgical and cosmetic procedures where soft tissue (i.e. a gland, organ, muscle, skin, ligament, tendon, cartilage, blood vessel or mesentery) support (through the load bearing function of the device) is desired, such as for example in breast reconstruction, breast augmentation, abdominal surgery, gastro-intestinal surgery, hernia repair and facial surgery.
  • soft tissue i.e. a gland, organ, muscle, skin, ligament, tendon, cartilage, blood vessel or mesentery
  • the soft tissue support can be provided by the device itself (for example in conjunction with a hernia repair) or by the device being used in conjunction with another implant, for example use of the device on or around a tissue expander or a breast implant used in a breast reconstruction or a breast augmentation surgical procedure.
  • Soft tissue support surgical meshes and scaffolds are known and are usually made of a synthetic polymer such as Teflon®, polypropylene, polyglycolic acid, polyester, or polyglactin 910.
  • Biomaterials such a tissue based or tissue derived material, for example an acellular dermal matrix (“ADM”) obtained from human and animal derived dermis have also been used but do not have the mechanical integrity of high load demand applications (e.g.
  • ligaments, tendons, muscle or the appropriate biological functionality because most biomaterials either degrade too rapidly (e.g., collagen, PLA, PGA, or related copolymers) or are non-degradable (e.g., polyesters, metal), and in either case functional autologous tissue ingrowth (important to assist transfer of a load bearing function from an implanted biomaterial as the biomaterial is bioresorbed by the body) occurs very little or fails to occur.
  • a biomaterial may misdirect tissue differentiation and development (e.g. spontaneous bone formation, tumors) because it lacks biocompatibility with surrounding cells and tissue.
  • a biomaterial that fails to degrade typically is associated with chronic inflammation and such a response is detrimental to (i.e. weakens) surrounding and adjacent tissue.
  • Silk is a natural (non-synthetic) protein made of high strength fibroin fibers with mechanical properties similar to or better than many of synthetic high performance fibers. Silk is also stable at physiological temperatures in a wide range of pH, and is insoluble in most aqueous and organic solvents. As a protein, unlike the case with most if not all synthetic polymers, the degradation products (e.g. peptides, amino acids) of silk are biocompatible. Silk is non-mammalian derived and carries far less bioburden than other comparable natural biomaterials (e.g. bovine or porcine derived collagen). Silk, as the term is generally known in the art, means a filamentous fiber product secreted by an organism such as a silkworm or spider.
  • Silks can be made by certain insects such as for example Bombyx mori silkworms, and Nephilia clavipes spiders. There are many variants of natural silk. Fibroin is produced and secreted by a silkworm's two silk glands. As fibroin leaves the glands it is coated with sericin a glue-like substance. Spider silk s produced as a single filament lacking the immunogenic protein sericin. Use of both silkworm silk and spider silk (from a natural source or made recombinantly) is within the scope of the present invention.
  • Silkworm silk has been used in biomedical applications.
  • the Bombyx mori species of silkworm produces a silk fiber (a “bave”) and uses the fiber to build its cocoon.
  • the bave as produced include two fibroin filaments or broins which are surrounded with a coating of the gummy, antigenic protein sericin.
  • Silk fibers harvested for making textiles, sutures and clothing are not sericin extracted or are sericin depleted or only to a minor extent and typically the silk remains at least 10% to 26% by weight sericin. Retaining the sericin coating protects the frail fibroin filaments from fraying during textile manufacture.
  • textile grade silk is generally made of sericin coated silk fibroin fibers.
  • Medical grade silkworm silk is used as either as virgin silk suture, where the sericin has not been removed, or as a silk suture from which the sericin has been removed and replaced with a wax or silicone coating to provide a barrier between the silk fibroin and the body tissue and cells.
  • Physicians prefer and require an implantable, knitted silk medical device with the flexibility to be stretched, expanded, pulled into shape, elongated and/or draped into place over, around or under soft tissue or an implant at the time of a soft tissue surgical or medical procedure, without the silk medical device upon its elongation breaking, splitting or unraveling.
  • an implantable, knitted silk medical device with the flexibility to be stretched, expanded, pulled into shape, elongated and/or draped into place over, around or under soft tissue or an implant at the time of a soft tissue surgical or medical procedure, without the silk medical device upon its elongation breaking, splitting or unraveling.
  • the device in one embodiment is a pliable. knitted mesh having at least two yarns laid in a knit direction and engaging each other to define a plurality of nodes, the at least two yarns including a first yarn and a second yarn extending between and forming loops about two nodes, the second yarn having a higher tension at the two nodes than the first yarn, the second yarn substantially preventing the first yarn from moving at the two nodes and substantially preventing the knitted mesh from unraveling at the nodes.
  • the device is a surgical mesh made of silk that is knitted, multi-filament, and bioengineered. It is mechanically strong, biocompatible, and long-term bioresorbable. The sericin-extracted silkworm fibroin fibers of the device retain their native protein structure and have not been dissolved and/or reconstituted.
  • Bioresorbed means that none or fewer than 10% of the silk fibroin fibers of the device can be seen to the naked (no magnification aid) eye upon visual inspection of the site of implantation of the device or of a biopsy specimen therefrom, and/or that the device is not palpable (i.e. cannot be felt by a surgeon at a time after the surgery during which the device was implanted) upon tactile manipulation of the dermal location of the patient at which the device was implanted. Typically either or both of these bioresorbed determinants occur about 1 to about 5 years are in vivo implantation of the device.
  • the device of the present invention is a pliable, sterile surgical mesh or scaffold available in a variety of shapes and sizes ready for use in open surgical or in laparoscopic procedures.
  • the device is flexible and well-suited for delivery through a laparoscopic trocar due to its strength, tear resistance, suture retention, and ability to be cut in any direction.
  • the device can provide immediate physical and mechanical stabilization of a tissue defect through the strength and porous (scaffold-like) construction of the device.
  • the device can be used as a transitory scaffold for soft tissue support and repair to reinforce deficiencies where weakness or voids exist that require the addition of material to obtain the desired surgical outcome.
  • the device can comprise filament twisted silk yarns.
  • the silk is made of silk fibroin fibers.
  • the silk fibroin fibers are preferably sericin depleted or sericin extracted silk fibroin fibers.
  • the device has an open pore knit structure.
  • the device and ingrown native tissue can maintain at least about 90% of the time zero device strength of the device at one month or at three months or at six months in vivo after the implantation.
  • the device can be implanted without regard to side orientation of the device and the combined thickness of the device and ingrowth of native tissue scaffold increases with time in vivo in the patient.
  • fibroin includes silkworm fibroin (i.e. from Bombyx mori ) and fibroin-like fibers obtained from spiders (i.e. from Nephila clavipes ).
  • silk protein suitable for use in the present invention can be obtained from a solution containing a genetically engineered silk, such as from bacteria, yeast, mammalian cells, transgenic animals or transgenic plants. See, for example, WO 97/08315 and U.S. Pat. No. 5,245,012.
  • the device is a pliable, knitted silk fabric intended for implantation in a human body.
  • the word “knit” is synonymous with the word “knitted”, so that a knit silk fabric is the same as a knitted silk fabric.
  • the device can be a warp knit or can be weft knit silk fabric.
  • the device according of the present invention is a pliable, biocompatible, warp knit, multi-filament silk fabric.
  • a woven material or fabric is made by weaving, which is a process that does not use needles, and results in a fabric with different characteristics.
  • a woven fabric is made by a non-needle process using multiple yarns that interlace each other at right angles to form a structure wherein one set of yarn is parallel to the direction of fabric formation.
  • Woven fabrics are classified as to weave or structure according to the manner in which warp and weft cross each other.
  • the three main types of weaves (woven fabrics) are plain, twill, and satin.
  • Woven (weaved) silk fabric, woven textiles and woven fabrics are not within the scope of the present invention.
  • Non-woven fabrics are also not within the scope of the present invention.
  • Non-woven (also refer to as bonded) fabrics are formed by having multiple fibers cohered together chemically or physically, without use of needles.
  • a knitted fabric is generally softer and more supple because its thread is treated differently.
  • a knitted fabric is made by using needles (such as for example the needles of a single or double bed knit machine) to pull threads up through the preceding thread formed into a loop by the needle.
  • needles such as for example the needles of a single or double bed knit machine
  • the knitted fabric can have one or multiple yarn intermeshing (also referred as interloping).
  • the device is made of biodegradable silk and is a biocompatible, non-woven, knit, multi-filament silk fabric or mesh.
  • Embodiments according to aspects of the present invention provide a biocompatible surgical silk mesh device for use in soft or hard tissue repair.
  • soft tissue repair include hernia repair, rotator cuff repair, cosmetic surgery, implementation of a bladder sling, or the like.
  • hard tissue repair such as bone repair, involve reconstructive plastic surgery, ortho trauma, or the like.
  • the open structure of the device allows tissue ingrowth as the silk forming the device is bioresorbed, at a rate permitting smooth transfer of mechanical properties to the new tissue from the device.
  • the device has a knit pattern that substantially or entirely prevents unraveling, especially when the device is cut.
  • the device have a stable knit pattern made by knitting silk yarn with variations of tension between at least two yarns laid in a knit direction. For example, a first yarn and a second yarn may be laid in a knit direction to form “nodes” for a mesh device.
  • the knit direction for the at least two yarns for example, may be vertical during warp knitting or horizontal during weft knitting.
  • the nodes of a mesh device also known as intermesh loops, refer to intersections in the mesh device where the two yarns form a loop around a knitting needle.
  • the first yarn is applied to include greater slack than the second yarn, so that, when a load is applied to the mesh device, the first yarn is under a lower tension than the second device.
  • a load that places the at least two yarns under tension may result, for example, when the mesh device is sutured or if there is pulling on the mesh device.
  • the slack in the first yarn causes the first yarn to be effectively larger in diameter than the second yarn, so that the first yarn experiences greater frictional contact with the second yarn at a node and cannot move, or is “locked,” relative to the second yarn. Accordingly, this particular knit design may be referred to as a “node-lock” design.
  • the device bioresorbs at a rate sufficient that allows tissue in-growth while transferring the load-bearing responsibility to the native tissue.
  • An embodiment of the device can be made from Bombyx mori silkworm silk fibroin or from spider silk.
  • the raw silk fibers have a natural globular protein coating known as sericin, which may have antigenic properties and must be depleted before implantation. Accordingly, the yarn is taken through a depletion process as described, for example, by Gregory H. Altman et al., “Silk matrix for tissue engineered anterior cruciate ligaments,” Biomaterials 23 (2002), pp. 4131-4141, the contents of which are incorporated herein by reference.
  • the silk material used in the device embodiments contains substantially no (less than 5%) sericin.
  • a process for making the pliable, knitted silk mesh can have the steps of: knitting a first silk yarn in a first wale direction using the knit pattern 3/1-1/1-1/3-3/3; knitting a second silk yarn in a second wale direction using the knit pattern 1/1-1/3-3/3-3/1; knitting a third silk yarn in a first course direction using the knit pattern 3/3-3/3-5/5-5/5-3/3-3/3-5/5-5-1/1-1/1-5/5-5/5-3/3-3/3-5/5-5/5-3/3-3/3-7/7-7/7, and; knitting a fourth silk yarn in a second course direction using the knit pattern 1/1-5/5-5/5-3/3-3/3-5/5-5/5-3/3-3/3-7/7-7/7-3/3-3/3-5/5-5/5-3/3-3/3-5/5-5/5-1/1, thereby obtaining the pliable knitted silk mesh.
  • the two movements in the wale direction occur on separate needle beds, with alternate yarns, and with loops formed on the course movements staggered within the repeat knit pattern.
  • the silk yarns can be made of a nine filament, twisted, and sericin depleted silk fibers, and the yarns can be made with three ends of Td 20/22 raw silk twisted together in the S direction to form a ply with 20 tpi and further combining 3 of the resulting ply with 10 tpi in the Z direction.
  • the e stitch density or pick count for silk mesh design can be about 40 picks per centimeter including the total picks count for the technical front face and the technical back face of the mesh, or equivalently about 20 picks per cm considering only one face of the mesh.
  • a detailed process for making the pliable knitted silk mesh can have the steps of: knitting a first silk yarn in a first wale direction using the pattern 3/1-1/1-1/3-3/3; knitting a second silk yarn in a second wale direction using the pattern 1 /1-1/3-3/3-3/1; knitting a third silk yarn in a first course direction using the pattern 3/3-3/3-5/5-5/5-3/3-3/3-5/5-5-1/1-1/1-5/5-5/5-3/3-3/3-5/5-5/5-3/3-3/3-7/7-7/7, and; knitting a fourth silk yarn in a second course direction using the pattern 1/1-5/5-5/5-3/3-3/3-5/5-5/5-3/3-3/3-7/7-7/7-3/3-3/3-5/5-5/5-3/3-3/3-5/5-5/5-1/1, wherein: the two movements in the wale direction occur on separate needle beds with alternate yarns and loops that occur on every course are staggered within repeat; the silk yarns are made of a nine filament, twisted, and sericin depleted silk fibers; the yarns are
  • the pliable, knitted silk mesh can have percent elongation at break of between about 4% or 32% to about 109% or 110%, a burst strength of about 0.45 MPa, and a stiffness of about 25 N/mm.
  • a process for making a pliable, knitted silk mesh comprising the steps of: knitting a first silk yarn in a first wale direction using the knit pattern 3/1-1/1-1/3-3/3; knitting a second silk yarn in a second wale direction using the knit pattern 1/1-1/3-3/3-3/1, knitting a third silk yarn in a first course direction using the knit pattern 3/3-3/3-5/5-5/5-3/3-3/3-5/5-5/1/1-1/1-5/5-5/5-3/3-3/3-5/5-5/5-3/3-3/3-7/7-7/7, and; knitting a fourth silk yarn in a second course direction using the knit pattern 1/1-5/5-5/5-3/3-3/3-5/5-5/5-3/3-3/3-7/7-7/7-3/3-3/3-5/5-5/5-3/3-3/3-5/5-5/5-1/1,thereby obtaining the pliable knitted silk mesh.
  • the two movements in the wale direction occur on separate needle beds (a knitting machine having two needle beds); and (b) with alternate yarns such as they knit with the opposing needle bed to their location (the front set of yarn knit with the back needle bed and the back set of yarn knit with the front needle bed).
  • the silk yarns are made of a nine filaments (“filaments” can be defined as raw silk yarn having a finesse of about Td 20/22) of twisted, and sericin depleted silk fibers.
  • the yarns are made with three ends of raw silk yarn twisted together having a finesse of Td 20/22 twisted together in the S direction (clockwise direction of twist) to form a ply with 20 tpi (twist per inch is the number of twist measured in an inch of yarn) and further combining 3 of the resulting ply with 10 tpi in the Z direction(counter clockwise direction of twist), and the stitch density or pick count for silk mesh design is about 40 picks per centimeter including the total picks count for the technical front face and the technical back face of the mesh, or equivalently about 20 picks per cm considering only one face of the mesh.
  • Our invention also includes a process for making a pliable knitted silk mesh, the process comprising the steps of: knitting a first silk yarn in a first wale direction using the pattern 3/1-1/1-1/3-3/3; knitting a second silk yarn in a second wale direction using the pattern 1/1-1/3-3/3-3/1, knitting a third silk yarn in a first course direction using the pattern 3/3-3/3-5/5-5/5-3/3-3/3-5/5-5-1/1-1/1-5/5-5/5-3/3-3/3-5/5-5/5-3/3-3/3-7/7-7/7, and; knitting a fourth silk yarn in a second course direction using the pattern 1/1-5/5-5/5-3/3-3/3-5/5-5/5-3/3-3/3-7/7-7/7-3/3-3/3-5/5-5/5-3/3-3/3-5/5-5/5-1/1, wherein: (e) the two movements in the wale direction occur on separate needle beds with alternate yarns and loops that occur on every course are staggered within repeat; (f) the silk yarns are made of a nine filament, twisted, and sericin de
  • Our invention also includes a pliable knitted silk mesh made by: knitting a first silk yarn in a first wale direction using the pattern 3/1-1/1-1/3-3/3; knitting a second silk yarn in a second wale direction using the pattern 1/1-1/3-3/3-3/1, knitting a third silk yarn in a first course direction using the pattern 3/3-3/3-5/5-5/5-3/3-3/3-5/5-5/1/1-1/1-5/5-5/5-3/3-3/3-5/5-5/5-3/3-3/3-7/7-7/7, and; knitting a fourth silk yarn in a second course direction using the pattern 1/1-5/5-5/5-3/3-3/3-5/5-5/5-3/3-3/3-7/7-7/7-3/3-3/3-5/5-5/5-3/3-3/3- 5/5-1/1.
  • the silk yarns are made of a nine filament, twisted, and sericin depleted silk fibers, and; the yarns are made with 3 ends of Td 20/22 raw silk twisted together in the S direction to form a ply with 20 tpi and further combining 3 of the resulting ply with 10 tpi in the Z direction, and; the stitch density or pick count for silk mesh design is 40 picks per centimeter including the total picks count for the technical front face and the technical back face of the mesh, or equivalently 20 picks per cm considering only one face of the mesh.
  • Our invention also includes a pliable knitted silk mesh made by: knitting a first silk yarn in a first wale direction using the pattern 3/1-1/1-1/3-3/3; knitting a second silk yarn in a second wale direction using the pattern 1/1-1/3-3/3-3/1, knitting a third silk yarn in a first course direction using the pattern 3/3-3/3-5/5-5/5-3/3-3/3-5/5-5/1/1-1/1-5/5-5/5-3/3-3/3-5/5-5/5-3/3-3/3-7/7-7/7, and; knitting a fourth silk yarn in a second course direction using the pattern 1/1-5/5-5/5-3/3-3/3-5/5-5/5-3/3-3/3-7/7-7/7-3/3-3/3-5/5-5/5-3/3-3-3-3-3-3- 5/5-5/1/1, wherein: (e) the two movements in the wale direction occur on separate needle beds with alternate yarns and loops that occur on every course are staggered within repeat; (f) the silk yarns are made of a nine filament, twisted, and sericin depleted silk fibers; (g
  • FIG. 1A is a photograph of a pattern layout for a silk-based scaffold design in accordance with the present invention.
  • FIGS. 1B and 1C illustrate an example pattern layout for the scaffold design of FIG. 1A including all pattern and ground bars according to aspects of the present invention.
  • FIGS. 1D and 1E illustrate an example pattern layout for a double needle bed mesh or scaffold according to aspects of the present invention from FIG. 1B for ground bar # 4 .
  • FIGS. 1F and 1G illustrate an example pattern layout for a double needle bed mesh or scaffold according to aspects of the present invention from FIG. 1B for pattern bar # 5 .
  • FIGS. 1H and 1I illustrate an example pattern layout for a double needle bed mesh or scaffold according to aspects of the present invention from FIG. 1B for ground bar # 7 .
  • FIG. 1J illustrates an example pattern simulation for a double needle bed mesh demonstrated in FIG. 1B according to aspects of the present invention.
  • FIG. 1K shows the yarn feed rates used during the knit process used to make the most preferred embodiment of the device within the scope of the present invention.
  • FIG. 2 illustrates the twisting and multi-ply nature of a yarn comprised of silk fibroin bundles as used in an embodiment of the present invention.
  • FIG. 3A shows a scanning electromicrograph (“SEM”) of native silk fibers.
  • FIG. 3B shows a SEM of sericin extracted silk fibers useful to make the device.
  • the size bar at the top of each of FIG. 3A and FIG. 3B measures 20 microns.
  • FIG. 4 is a photograph of an embodiment (a knitted silk fabric ready for implantation) of a device within the scope of the present invention (placed above a millimeter ruler).
  • FIG. 5A is photograph at 16 ⁇ magnification of a portion of the FIG. 4 embodiment.
  • FIG. 5B is photograph of the FIG. 4 embodiment showing the ease with which it can be cut without the fabric unraveling or fraying.
  • FIG. 6 is a photograph of a pattern layout for a silk-based scaffold design in accordance with the present invention (“the device” of Example 1)
  • FIG. 7 represents one of the element for the pattern layout making the device on a raschel knitting machine.
  • 7 A is the needle layout over two needle bed (front and back);
  • 7 B represent the yarn evaluation for the 4 bars making the device in FIG. 6 ;
  • 7 C is one of the grid equivalent to one needle space and one course (front or back of the pattern)
  • FIG. 8 represents one of the element for the pattern layout making the device on a raschel knitting machine.
  • 8 A is the threading sequence for the guide bar heddle, each color dot represent one heddle eyelet;
  • 8 B is the bar and devices numbering sequence.
  • FIG. 9 represents one of the element for the pattern layout making the device on a raschel knitting machine.
  • 9 A is the sequence for the movements making up the pattern bars;
  • 9 B is the sequence for the value making up the take down;
  • 9 C- 9 D- 9 E are the sequences for the feed rate of the yarn making up the pattern.
  • the present invention is based on discovery of an implantable, bioresorbable, biocompatible, pliable, knitted, porous silk mesh (the “device”) which upon implantation provides soft tissue support and, as the device bioresorbs, transfer of its load bearing (support) function to new tissue formed at the site of implantation.
  • the device is preferably made from Bombyx mori silkworm silk. It can also be made from spider silk, including recombinantly made spider silk.
  • the preferred knit pattern of the device accomplishes variation in tension between yarns at the knit nodes (the yarn interlocking loops) thereby preventing unraveling of the mesh when cut for use in surgery.
  • FIG. 5A shows a 16 ⁇ magnification of the device knit pattern and
  • FIG. 5B shows ease of cutting without fraying or unraveling.
  • the device made according to the present invention allows significant and consistent tissue ingrowth while bioresorbing at a rate which permits smooth transfer of load bearing support to the newly formed tissue.
  • the device is made of a biocompatible silk protein that is eventually bioresorbed.
  • the raw silk fibers obtained from Bombyx mori silkworms comprise a fibroin protein core filament coated with the antigenic globular protein sericin.
  • the sericin is removed or substantially all removed by hot aqueous (i.e. soap) extraction (wash) leaving behind fibroin protein filament consisting of layers of antiparallel beta sheets which provide both stiffness and toughness.
  • FIG. 3A is a SEM photograph of native (sericin coated) silk fibers, and FIG. 3B of the fibers after sericin extraction, as then used to make (knit) the device.
  • the porous knit structure of the device so made is shown by FIGS. 1A, 4 and 5 .
  • the multi-filament fibroin yarn is subsequently knitted into a three dimensional pattern to serve as soft tissue support and repair.
  • the resulting device is mechanically strong, flexible, and tear-resistant.
  • the device is a single use only scaffold that can be produced in a variety of shapes, sizes and thicknesses and can be terminally sterilized.
  • the device provides immediate physical and mechanical stabilization of tissue defects because of its strength and porous construction and is useful as a transitory scaffold for soft tissue support and repair. It provides reinforcement for deficiencies where weakness or voids exist that require additional material reinforcement to obtain the desired surgical outcome.
  • the bioresorption process occurs over time after implantation of the device as tissue in-growth and neovascularization takes place.
  • the device can be used to assist soft tissue repair.
  • soft tissue repair include breast reconstruction, hernia repair, cosmetic surgery, implementation of a bladder sling, or the like.
  • FIG. 1A is a photograph of a pattern layout for a device (silk-based mesh or scaffold) in accordance with the present invention.
  • FIG. 1A shows the wale direction 10 and the course direction 15 and placement of the silk yarns in either the wale 10 or course 15 scaffold material direction or location.
  • the device is preferably formed on a raschel knitting machine such as Comez DNB/EL-800-8B set up in 10 gg needle spacing by the use of three movements as shown in pattern layout in FIGS. 1B and 1C : two movements in the wale direction, the vertical direction within the fabric, and one movement in the course direction, the horizontal direction of the fabric.
  • the movements in the wale direction occur on separate needle beds with alternate yarns; loops that occur on every course are staggered within repeat.
  • the yarn follows a repeat pattern of 3/1-1 /1-1 /3-3/3 for one of the wale direction movements as shown in FIGS. 1D and 1E and 1/1-1/3-3/3-3/1 for the other wale direction movement as shown in FIGS. 1H and 11 .
  • the interlacing of the loops within the fabric allows for one yarn to become under more tension than the other under stress, locking it around the less tensioned yarn, thereby keeping the fabric from unraveling when cut.
  • the other movement in the course direction as shown in FIG. 1F and 1G occurs in every few courses creating the porous design of the device.
  • These yarns follow a repeat pattern of 7/7-9/9-7/7-9/9-7/7-9/9/-1/1-1/1-3/3-1/1-3/3-1/1-3/3-1/1-3/3-1/1-3/3- 1/1 for the course direction movement.
  • the pattern simulation layout of this pattern was rendered using ComezDraw 3 software in FIG.
  • FIG. 1J considering a yarn design made with 3 ends of Td (denier count) 20/22 raw silk twisted together in the S direction to form a ply with 20 tpi (turns per inch) and further combining three of the resulting ply with 10 tpi.
  • the same yarn design is used for the movements occurring in the wale and course directions.
  • the stitch density or pick count for the design in FIG. 1J is 34 picks per centimeter considering the total picks count for the technical front face and the technical back face of the fabric, or 17 picks per cm considering only on the face of the fabric.
  • the operating parameters described in FIGS. 1B to 1I are the optimum values for the specific yarn design used for the pattern simulation layout of FIG. 1J . In FIG.
  • 1J item 17 is a simulated double needle bed mesh or scaffold.
  • FIG. 1F following standard terminology well known in the knit industry “F” means front and “B” means back and with regard to FIG. 1F shows the incremental sequence of pattern lines for the course direction.
  • the numbers “12, 9, 6 and 3” at the bottom of FIG. 1F represent the number of needles in the needle bed starting count from left to right.
  • the upwards pointing arrows near the bottom of FIG. 1F show the needle slots occupied by a needle actively engaged with the yarn for the knit machine/knit process.
  • Rows 1F to 6B of FIG. 1F show the knit pattern used to make the device.
  • FIG. 1F following standard terminology well known in the knit industry “F” means front and “B” means back and with regard to FIG. 1F shows the incremental sequence of pattern lines for the course direction.
  • the numbers “12, 9, 6 and 3” at the bottom of FIG. 1F represent the number of needles in the needle bed starting count from left to right.
  • 1F rows 1F to 6B knit pattern is repeated 94 times to make a 25 cm sheet length of the fabric of the device, the number of repeats of the pattern being fewer or more if respectively a smaller or larger section of device fabric is desired to result from the knit process.
  • the FIG. 1F rows 1F to 6B knit pattern is equivalently described by the above set forth, combined three knit movement: the first wale direction 3/1-1 /1-1 /3-3/3 knit pattern; the second wale direction 1/1-1/3-3/3-3/1 knit pattern, and; the course direction 7/7-9/9-7/7-9/9-7/7-9/9/-1/1-1/1-3/3-1/1-3/3-1/1 knit pattern. Rows 7F to 10B in FIG.
  • FIG. 1F shows the knit pattern used to make a spacer which creates a kitted area of fabric separation (i.e. a cut location) between adjacent 25 cm lengths of the knitted device fabric which is knitted by the process set forth above as one continuous sheet of fabric.
  • the specific feed rates for the yarn forming this most preferred embodiment of the device is shown in FIG. 1K where column 17 shows the yarn feed rate used for the first wale direction 3/1-1 /1-1 /3-3/3 knit pattern.
  • a rate of 212 is equivalent to 74.8 cm of yarn per 480 coursed or per rack.
  • 1K reports the yarn feed rate that is used for the second wale direction 1/1-1/3-3/3-3/1 knit pattern, where again a rate of 212 is equivalent to 74.8 cm of yarn per 480 coursed or per rack.
  • Column 22 of FIG. 1K shows the yarn feed rate that is used for the course direction 7/7-9/9-7/7-9/9-7/7-9/9/-1/1-1/1-3/3-1/1-3/3-1/1-3/3-1/1-3/3-1/1-3/3-1/1-3/3-1/1-3/3-1/1-3/3-1/1-3/3-1/1 knit pattern; a rate from line 1F to 6B of 190 is equivalent to 67.0 cm of yarn per 480 coursed or per rack, while a rate from line 7F to 10B of 90 is equivalent to 31.7 cm of yarn per 480 coursed or per rack.
  • 1K shows that the yarn feed rate that is used for the second to last yarn at each edge of the knitted device fabric in the course direction 7/7-9/9-7/7-9/9-7/7-9/9/-1/1-1/1-3/3-1/1-3/3-1/1-3/3-1/1-3/3-1/1-3/3-1/1-3/3-1/1-3/3-1/1 knit pattern; a rate from line 1F to 6B of 130 is equivalent to 45.8 cm of yarn per 480 coursed or per rack, while a rate from line 7F to 10B of 90 is equivalent to 31.7 cm of yarn per 480 coursed or per rack.
  • 1K reports (shows) the yarn feed rate that is used for the last yarn at each edge of the knitted device fabric in the course direction 7/7-9/9-7/7-9/9-7/7-9/9/-1/1-1/1-3/3-1/1-3/3-1/1-3/3-1/1-3/3-1/1-3/3-1/1-3/3-1/1-3/3-1/1 knit pattern; a rate from line 1F to 6B of 130 is equivalent to 45.8 cm of yarn per 480 coursed or per rack, while a rate from line 7F to 10B of 90 is equivalent to 31.7 cm of yarn per 480 coursed or per rack.
  • the knit pattern shown in FIG. 1A can be knit to any width depending upon the knitting machine and can be knitted with any of the gauges available with the various crochet machines or warp knitting machines.
  • Table 1 outlines the device fabric widths that may be achieved using a different numbers of needles on different gauge machines. The dimensions in Table 1 are approximate due to the shrink factor of the knitted fabric which depends on stitch design, stitch density, and yarn size used.
  • the device was knit with 9-filament, twisted silk yarns.
  • a yarn was made from three silk bundles, each of which was comprised of individual silk fibrils as illustrated in FIG. 2 .
  • the 9-filament yarns were knit into the surgical scaffold. The wales ran horizontally and the courses ran vertically along the scaffold.
  • a preferred embodiment of the device ready for surgical use has a thickness between about 0.6 mm and about 1.0 mm, a width of about 10 cm ( ⁇ about 1 cm) and a length of about 25 cm ( ⁇ about 3 cm). Additionally the device has pores with an average diameter greater than about 10,000 um 2 , a density of from about 0.14 mg/mm 3 to about 0.18 mg/mm 3 (as determined by dividing the mass of the device by its volume [thickness, width, and length multiplied together]), and is comprised of at least about 95% silk fibroin.
  • the device has a burst strength of from about 0.54 MPa to about 1.27 MPa, and a stiffness of between about 30N/mm to about 50 N.mm (the latter two mechanical properties of the preferred device determined by American Society for Testing and Materials D3787-07, “Standard Method for Burst Strength of Textiles: Constant Rate of Transverse Ball Burst Test” or ASTM F2150-07 Standard Guide for Characterization and Testing of Biomaterial Scaffolds Used in Tissue Engineered Medical Products)
  • the density of the device was calculated using the equation:
  • the cross-sectional area of full pores of the scaffold was measured using a microscope with sufficient magnification and image capture capability. The magnification was selected based upon the resolution of the pores in the knit pattern being examined.
  • each device tested was compressed between the two circular fixation brackets of the mechanical testing equipment, while leaving exposed a circular area of the test article that covers the radius of the inner fixture diameter.
  • the sample device was secured with a constant fixation bolt torque to the locking nuts of the burst jig. Care was taken to ensure that the knit structure of the sample was organized and not skewed or sheared. The sample remained taut within the fixation brackets with equal distribution of tension.
  • the ball burst fixture was attached to the mechanical testing equipment with a calibrated load cell. For the burst test, the fixture ball was inserted through the center diameter of the fixation brackets with a uniform pressure applied to the test article. The ball was inserted at a constant rate until the scaffold fails.
  • Burst stiffness was calculated by determining the slope of the middle 60% of the linear region of the compressive load vs. extension curve.
  • the exposed area was the circular area of the test article covering the radius (r) of the inner fixture diameter and was calculated using the equation below.
  • the tensile strength and elongation of the device were measured in accordance with ASTM D5035.
  • Device samples were clamped in the mechanical test equipment.
  • the upper clamp was mounted to the load cell, which was attached to the actuator and the lower clamp was mounted to the support plate.
  • the lower limit of the actuator was set so that the upper and lower clamps were prevented from colliding.
  • the upper clamp was aligned to make the faces of both clamps parallel to each other.
  • the height of the mechanical equipment crosshead was adjusted so that the actuator was positioned to allow for a defined amount of upward movement and a specific sample gauge length resided between the upper and lower sample clamps.
  • the device was loaded by clamping the first 10 mm of the sample into the upper clamp and allowing the remainder of the sample to fall unrestrained into the bottom clamp opening. The last 10 mm of the sample was held by the bottom clamp. Care was taken to avoid pre-staining the device sample.
  • the actuator height was adjusted so that the sample had a pre-load of 2N.
  • the actuator position was adjusted to achieve a specific gauge length and then reset to the zero-position at this point.
  • the device sample was strained until it experienced ultimate tensile failure.
  • the average maximum tensile strength, maximum tensile stress, percent elongation at break, and the tensile stiffness were determined. Tensile stiffness was calculated by determining the slope of the trend line of the linear portion of the tensile load vs. elongation curve bound by an upper and lower tensile load.
  • Tensile stiffness was calculated as the slope of the linear portion of the load verses elongation curve. The average maximum tensile strength, maximum tensile stress, linear stiffness, and percent elongation at break were determined.
  • the thickness and width were provided by the respective device sample thickness and width measurements.
  • PercentElongationatBreak ⁇ [ % ] [ Elongation ⁇ ⁇ at ⁇ ⁇ Break ⁇ [ mm ] Length ⁇ [ mm ] ] ⁇ ⁇ %
  • Tear testing A device sample with a width that is two-thirds that of the length was cut from each device. Before the samples are incubated in phosphate buffered saline, a small cut that was one-fourth the size of the sample width was made in the center of the device sample perpendicular to the length (through a single row of wales). Mechanical test equipment was used to measure the maximum tear resistance load. Clamps were inserted in the equipment. The upper clamp was mounted to the load cell that was attached to the actuator and the lower clamp was mounted to the base support plate. The lower limit of the actuator was set so that the upper and lower clamps were prevented from colliding. The upper clamp was aligned to make the faces of both clamps parallel to each other.
  • the height of the mechanical equipment crosshead was adjusted so that the actuator was positioned to allow for a defined amount of upward movement and a specific sample gauge length resided between the upper and lower clamps.
  • the device sample was placed in the upper clamp. The top 10 mm of the sample was covered by the clamp. The device sample was positioned so that the cut was located on the left side. The sample was aligned perpendicular with the clamp before the clamp was closed. The bottom portion of the sample was allowed to fall unrestrained into the bottom clamp opening. The clamp was closed and the sample was preloaded with 3N. The sample was strained at a constant rate until the sample tore at the cut point. From the resulting data the maximum tear resistance load was obtained.
  • Embodiments of the device according to the present invention can be knitted on a fine gauge crochet knitting machine.
  • a non-limiting list of crochet machines capable of manufacturing the surgical mesh according to aspects of the present invention are provided by: Changde Textile Machinery Co., Ltd.; Comez; China Textile Machinery Co., Ltd.; Huibang Machine; Jakkob Muller AG; Jingwei Textile Machinery Co., Ltd.; Zhejiang Jingyi Textile Machinery Co., Ltd.; Dongguan Kyang the Delicate Machine Co., Ltd.; Karl Mayer; S rotating Machine; Sino Techfull; Suzhou Huilong Textile Machinary Co., Ltd.; Taiwan Giu Chun Ind. Co., Ltd.; Zhangjiagang Victor Textile; Liba; Lucas; Muller Frick; and Texma.
  • Embodiments of the device according to the present invention can be knitted on a fine gauge warp knitting machine.
  • warp knitting machines capable of manufacturing the surgical mesh according to aspects of the present invention are provided by: Comez; Diba; Jingwei Textile Machinery; Liba; Lucas; Karl Mayer; Muller Frick; Runyuan Warp Knitting; Taiwan Giu Chun Ind.; Fujian Xingang Textile Machinery; and Yuejian Group.
  • Embodiments of the device according to the present invention can be knitted on a fine gauge flat bed knitting machine.
  • a non-limiting list of flat bed machines capable of manufacturing the surgical mesh according to aspects of the present invention are provided by: Around Star; Boosan; Cixing Textile Machine; Fengshen; Flying Tiger Machinary; Fujian Hongqi; G & P; Görteks; Jinlong; JP; Jy Leh; Kauo Heng Co., Ltd.; Matsuya; Nan Sing Machinery Limited; Nantong Sansi Instrument; Shima Seiki; Nantong Tianyuan; and Ningbo Yuren Knitting.
  • a test method was developed to check the cutability of the device formed according to aspects of the present invention.
  • the device evaluated according to the number of scissor strokes needed to cut the device with surgical scissors.
  • the mesh was found to cut excellently because it took only one scissor stroke to cut through it.
  • the device was also cut diagonally and in circular patterns determining that the device did not unraveled once cut in either or both its length and width directions (see FIG. 5B ). To determine further if the device would unravel a suture was passed through the closest pore from the cut edge, and pulled. This manipulation did not unravel the device. Thus the device was easy to cut and did not unravel after manipulation.
  • a device according to the present invention has been found to bioresorb by 50% in approximately 100 days after implantation, that is at least about 50% of the mass of the device bioresorbs after about 100 days after implantation in a human patient.
  • Physical properties of the device include thickness, density and pore sizes.
  • the thickness of the device was measured utilizing a J100 Kafer Dial Thickness Gauge.
  • a Mitutoyo Digimatic Caliper was used to find the length and width of the samples; used to calculate the density of the device.
  • the density was found by multiplying the length, width and thickness of the mesh then dividing the resulting value by the mass.
  • the pore size of the device was found by photographing the mesh with an Olympus SZX7 Dissection Microscope under 0.8 ⁇ magnification. The measurements were taken using ImagePro 5.1 software and the values were averaged over several measurements. Physical characteristics of sample meshes, and two embodiments of the device are shown in Table 2.
  • the device in Examples 1-6
  • pliable it is meant that the device can stretched to increase its length and/or its width by between about 4% to about 110% before breaking (see Table 5 below).
  • the device is a pliable, knitted, biocompatible silk scaffold device that can be implanted in a surgical procedure to provide soft tissue repair and soft tissue support, including to support an implant such as a breast implant or a tissue expander.
  • soft tissue repair surgical procedures include breast reconstruction, hernia repair, cosmetic surgery, and implementation of a bladder sling.
  • the device can employ a variety of polymer materials, preferable the device is made of silk, such as Bombyx Mori silkworm silk fibroin.
  • the raw silk fibers used to make the device have a natural globular protein coating known as sericin, which may have antigenic properties and must be depleted before implantation of the device. Accordingly, yarn used to make the device is taken through a sericin depletion process as described in Altman et al., “Silk matrix for tissue engineered anterior cruciate ligaments,” Biomaterials 23 (2002), pp. 4131-4141, the contents of which are incorporated herein by reference in its entirety. After the depletion process the silk material used in the device embodiments contains substantially no sensitizing agents.
  • the device is preferably made by knitting sericin depleted silk yarn to form a porous mesh or fabric.
  • the knitting can be carried out as raschel knitting, warp knitting and weft knitting.
  • the fabric of the device can be treated to enhance one or more device characteristics.
  • the device treatment can be a finishing or surface coating process which can increase device hydrophilicity, biocompatibility and mechanical properties, such as handling for ease of cutting and graft pull-through, as well as add an anti-microbial or anti-fungal coatings.
  • Specific examples of device surface treatments can include:
  • devices of varying width were made using different numbers of needles (needle count) on different gauge knitting machines.
  • the device can be knit to any width limited by the knitting machine width and could be knitted with any of the gauges available with the various warp knitting machine.
  • Embodiments of a prosthetic device according to our invention can be knitted on a fine gauge warp knitting machine.
  • warp knitting machines capable of manufacturing the device: Comez; Diba; Jingwei Textile Machinery; Liba; Lucas; Karl Mayer; Muller Frick; Runyuan Warp Knitting; Taiwan Giu Chun Ind.; Fujian Xingang Textile Machinery; and Yuejian Group.
  • Embodiments of the device were knitted on a COMEZ DNB/EL-800-8B/P ⁇ 20 warp knitting machine in 20 gauge with stroke for each of the positions from 1 through 30 as shown in Table 4.
  • Our device has deformation properties that can be controlled by varying parameters within the device design, as set forth below to achieve desired device deformation (“i.e. pliable”) properties.
  • a preferred and desired deformation property is the ability of the knitted device to exhibit at least about a 30-35% extension of its length in the machine direction and at least about 25-30% extension of its length in the cross direction without breaking or unraveling. These device properties are desired because they provide stretch or pliability for the physician user at the time of device implantation, therefor permitting the user to alter the device dimensions at the time of device implantation.
  • FIG. 6 is a photograph of an embodiment of a pattern layout for the device, showing a silk-based scaffold design.
  • item A is a hexagonal or diamond shaped pore device each with a square area of about 4 square millimeters, other shape configuration may be designed such as round or polygonal as well as a different square area value.
  • This device is preferably created on a raschel knitting machine such as Comez DNB/EL-800-8B-P set up in 10 gg needle spacing by the use of four movements as shown by the pattern layout in FIG. 7 and FIG. 8 and FIG. 9 with two movements in the wale direction, the vertical direction within the fabric, and two movements in the course direction, the horizontal direction of the fabric.
  • the movements in the wale direction occur on separate needle beds with alternate yarns; loops that occur on every course are staggered within repeat. While being knit the yarn follows a repeat pattern of 3/1-1 /1-1 /3-3/3 for one of the wale direction movements and 1/1-1/3-3/3-3/1 for the other wale direction movement, with each number representing a position, each “I” representing a guide bar movement, and each “-” representing a course (or stitch). For example, a yarn following a pattern of 3/1-1/1-1/3-3/3 would start in position 3 (located between the second and third needle slots) and move, as indicated by the “I”, to position 1.
  • the knitting needles would form a stitch (as indicated by the “-”), remain in position 1 (since 1/1 represents no movement), form another stitch, move from position 1 to position 3, form another stitch, and then remain in position 3 (since 3/3 would also represent no movement).
  • the pattern would repeat for the full length of the fabric. The same notation method can be applied to all stitch patterns and on all guide bars listed.
  • the interlacing of the loops within the fabric of the device as it is being knit allow for one yarn to be under more tension than the other under stress, locking it around the less tensioned yarn; keeping the fabric from unraveling when cut.
  • One of the other two movements in the course direction occurs in every few courses creating the porous design of the scaffold. As being knit these yarns follow a repeat pattern of 3/3-3/3-5/5-5/5-3/3-3/3-5/5-5/5-1/1-1/1-5/5-5/5-3/3- 3/3-5/5-5/5-3/3-3/3-7/7-7/7 for the course direction movement.
  • the other movements in the course direction occur in every few courses creating the openings in the scaffold.
  • the pattern adopts a yarn design made with 3 ends of Td 20/22 raw silk twisted together in the S direction to form a ply with 20 tpi and further combining 3 of the resulting ply with 10 tpi in the Z direction.
  • the same yarn design is used for the movements occurring in the wale and course directions.
  • the stitch density or pick count for the scaffold design is preferably 40 picks per centimeter including the total picks count for the technical front face and the technical back face of the fabric, or equivalently 20 picks per cm considering only one face of the fabric.
  • the operating parameters are not limited to those described but just the optimum values for the physical properties of the device as a mesh or scaffold with the knit structure set forth which includes a twisted yarn. Sericin is preferably removed from the silk fibroin fibers after the yarn is formed (that is after the silk fibroin fibers have been twisted together, but not yet knitted) but before the mesh has been knit and/or after the device has been knitted.
  • a preferred embodiment of the device is made of a 9 filament, twisted, and purified (sericin depleted) silk fiber.
  • the yarn is then warp knitted as set forth above to thereby make the device.
  • the properties of the device include improved drapability, stretch, and conformability as compared to SERI standard 102 (SERI Surgical Scaffold), as shown in Table 5 below, where “SERI Standard 102” is the known SERI® Surgical Scaffold, and “SERI Pliable Sterilized” is the present device.
  • Table 5 properties were achieved, in part, by creating a symmetrical, diamond shaped pore that allows for bidirectional stretch. Selected further physical properties of an embodiment of the device are shown by Table 6.
  • the pliable silk device of Example 1 (“the device”) can be used as a transitory scaffold for soft tissue support and repair in two-stage breast reconstruction to reinforce deficiencies where weakness or voids existed that required the addition of material to obtain the desired surgical outcome.
  • the device is supplied sterile in a with one device utilized per breast.
  • the device placed during each subject's stage I breast reconstruction with a tissue expander placement procedure. Following mastectomy (either immediate or delayed), the surgical site is readied for subpectoral tissue expander insertion in accordance with standard surgical methods.
  • the tissue expander is rinsed in antibiotic solution (according to standard of care) and inserted into the subpectoral pocket.
  • the device s cut to size (prior to, during, and/or after suturing) to repair the void between the pectoral muscle and the chest wall (i.e., inframammary fold region).
  • the device is rinsed with antibiotic solution and sutured in place, with a minimum suture bite of 3 mm or one full row of material. If any cutting is performed in situ, rinsing of the implant site is performed. Intra-operative photography is taken of the device prior to closure.
  • the tissue expander is filled as appropriate, drains placed according to usual standard of care and number and location of drain(s) noted. Standard rinsing of the surgical site and closure is performed. Prophylactic antibiotic use and duration is documented.
  • tissue expander is removed and replaced with a breast implant.
  • the surgical approach used to remove the tissue expander Implant placement is subpectoralis muscle and the pocket is prepared.
  • the breast implant is rinsed in antibiotic solution and positioned within the pocket. Closure is performed.
  • the device provides soft tissue support and facilitates positioning of the implanted tissue expander.
  • the stage I implanted expander is a temporary implant.
  • the stage II breast implant is intended to be a permanent implant, typically remaining implanted in the patient for ten or more years.
  • the device also provides stabilization of the pectoralis muscle and can as well assist with maintenance of the position and appearance of the inframammary fold during stage I of a breast reconstruction and can provide this function after stage I as well.
  • stage II when the tissue expander is removed and the breast implant is implanted
  • the device is then fully or at least partially integrated within the underlying soft tissue which has grown into and around the pores of the scaffold.
  • the device begins to be bioresorbed as soon as the device had been implanted in a patient and the device is completely bioresorbed after about one to four years after implantation.
  • the device is implanted at stage I to help hold the tissue expander in place (the device is sutured in to form a pocket in which the tissue expander rests and/or the device is draped over the tissue expander).
  • stage II when the tissue expander is removed and replaced by a breast implant (saline or gel filled) the device is not removed and the device remains in place within the patient.
  • no additional or further device is implanted in the patient at stage II or thereafter.
  • the device implanted in the patient in stage I provides soft tissue support and along with the implanted tissue expander maintains the existence of a pocket or space during stage I (the tissue expansion stage) that is until the stage II breast implant implantation in the patient into the pocket or space so maintained during stage I.
  • the device assists to ensure that a pocket or space is available for the placement of the stage II breast implant.
  • the stage I implanted device is left in place implanted in the patient and is not removed. By stage II the device has be incorporated into the underlying soft tissue and vasculature has grown in and around it.
  • the scaffold is comprised entirely of or consists essentially of sericin depleted, knitted silkworm silk.
  • the implanted device begins to be biodegraded or bioresorbed as soon as it is implanted in a patient.
  • the fabric is completely (100%) bioresorbed (biodegraded) within about one year to about four years after implantation in a patient.
  • the device of Example 1 is supplied sterile in a single-use size with one device utilized per breast.
  • the device is implanted in the subject immediately post mastectomy, during the breast implant placement surgery, in a direct-to-implant breast reconstruction procedure.
  • the device is used in in DTI breast reconstruction is used.
  • the surgical site is readied for subpectoral breast implant insertion in accordance with standard surgical methods.
  • the breast implant is rinsed in antibiotic solution and inserted into the subpectoral pocket.
  • the device is optionally cut to size (prior to, during, and/or after suturing) to repair the void between the pectoral muscle and the chest wall (i.e., inframammary fold region).
  • the device is rinsed with antibiotic solution and sutured in place to both the pectoralis muscle and chest wall, with a minimum suture bite of 3 mm or one full row of material. If any cutting was performed in situ, rinsing of the implant site is performed. Drains are placed according to usual standard of care and number and location of drain(s) noted.
  • the device can be used as a transitory scaffold for soft tissue support and repair to reinforce deficiencies where weakness or voids exist that require the addition of material to obtain the desired surgical outcome, including but not limited to reinforcement of soft tissues in reconstructive and plastic surgery to obtain the desired aesthetic outcome.
  • the device should not be used in patients with a known allergy to silk nor in direct contact with bowel or viscera where formation of adhesions may occur. To use the device:
  • open hernia repair is a traditional hernia repair procedure.
  • approaches for performing this type of hernia repair are performed routinely with local and intravenous sedation. Due to the larger size of the incision, open hernia repair is generally painful with a relatively long recovery period.
  • Minimally invasive (laparoscopic) repair is usually performed under general anesthesia. Spinal anesthesia and local anesthesia are used under certain circumstances. Benefits associated with minimally invasive (laparoscopic) repair include shorter operative time, less pain, and a shorter recovery period.
  • a telescope attached to a camera is inserted through a small incision that is made under the patient's belly button. Two other small cuts are made in the lower abdomen.
  • the hernia defect is reinforced with a mesh and secured in position.
  • the device is secured in position by stitches, staples, tacks, and glue.
  • ventral hernia repair Another form of laparoscopic hernia repair is ventral hernia repair (laparoscopic).
  • Incisional, ventral, epigastric, or umbilical hernias are defects of the anterior abdominal wall and may be congenital (umbilical hernia) or acquired (incisional).
  • Incisional hernias form after surgery through the incision site or previous drain sites, or laparoscopic trocar insertion sites. Incisional hernias often occur after open surgical procedures. These hernias present with a bulge near or at a previous incision.
  • the device (a prosthetic mesh) is used in order to minimize tension on the repair so as to reduce the chance of hernia recurrence.
  • an old incision scar is incised and removed.
  • the device is used to cover the defect before closure of the wound. This is a major and often complex surgical procedure.
  • the use of the device decreases possible recurrence.
  • a patient typically returns to normal activity within a matter of weeks.
  • the principles governing a laparoscopic ventral hernia repair are based on those of open Stoppa ventral hernia repair.
  • a large piece of the device is placed under the hernia defect with a wide margin of mesh outside the defect, and the mesh is anchored in to place and secured to the anterior abdominal wall. The device is anchored into place, for example, by sutures.
  • the device is secured to the anterior abdominal wall, for example, by tacks which are placed laparoscopically.
  • the device can be used in body aesthetics and body contouring surgical procedures.
  • One such embodiment relates to use of the device in abdominoplasty.
  • the time needed for conducting an abdominoplasty also varies depending upon the type of abdominoplasty to be performed. For example, a complete abdominoplasty typically is completed in 1 to 5 hours.
  • a partial abdominoplasty, also referred to as a mini-tuck abdominoplasty is typically completed in 1 to 2 hours.
  • reconstruction of the umbilicus commonly referred to as the belly button, may also occur.
  • the original umbilicus is attached, such as by sutures, into a new hole created by the surgeon.
  • a complete abdominoplasty is also referred to as a full abdominoplasty.
  • a complete abdominoplasty an incision is made from hip to hip just above the pubic area. Another incision is made to separate the navel from the surrounding skin. The skin is detached from the abdominal wall to reveal the muscles and fascia to be tightened. The muscle fascia wall is tightened with sutures. The remaining skin and fat are tightened by removing the excess and closing. The old belly button stalk is brought out through a new hole and sutured into place. Liposuction may also be used to refine the transition zones of the abdominal contouring. A surgical dressing and optionally a compression garment are applied. Excess fluid from the site is drained.
  • a complete abdominoplasty may also comprise a musculofascial plication abdominal dermal lipectomy and/or suction-assisted lipectomy of hips.
  • a partial abdominoplasty is also referred to as a mini abdominoplasty.
  • a partial abdominoplasty a smaller incision is made as compared to a complete abdominoplasty.
  • the skin and fat of the lower abdomen are detached in a more limited manner from the muscle fascia.
  • the skin is stretched down and excess skin removed.
  • the belly button stalk may be divided from the muscle below and the belly button slid down lower on the abdominal wall.
  • a portion of the abdominal muscle fascia wall is optionally tightened. Liposuction is often used to contour or sculpt the transition zone. The flap is stitched back into place. A combination abdominoplasty and liposuction procedure is often referred to as a “lipo-tuck”. During such procedure, skin is removed and subsequently sutured. As noted above, the belly button is reattached to a new hole created by the surgeon.
  • An extended abdominoplasty is a complete abdominoplasty plus a lateral thigh lift.
  • the patient is cut from the posterior axillary line.
  • the operation includes all of the abdominal contouring of a complete abdominoplasty plus allows further improvement of the flank (waist), as well as smoothing the contour of the upper lateral thigh.
  • a high lateral tension tummy tuck is a more involved procedure and typically takes at least four and half hours to perform.
  • muscles are also tightened horizontally. The procedure provides a patient with a flat abdomen and with an improved waistline.
  • a circumferential abdominoplasty also referred to as a belt lipectomy or body lift, is an extended abdominoplasty in conjunction with a buttock lift.
  • the incision typically runs all the way around the body. This surgical procedure is suitable, for example, for patients who have undergone massive weight loss.
  • an abdominoplasty may be conducted in the course of a lower body lift.
  • abdominoplasty is combinable with liposuction contouring, breast reduction, breast lift, or a hysterectomy.
  • Breast enhancement procedures performed in conjunction with an abdominoplasty are often referred to as a “mommy makeover”. In such a procedure, barbed sutures may be employed.
  • An abdominoplasty procedure can be conducted using the device
  • the typical fascial is done first, using a row of figure of eight sutures, first and then another layer of running suture all #1 PDS (polydioxanone suture, Ethicon)
  • Two pieces of the device can be used as an onlay to augment the fascia tightening.
  • One 10 ⁇ 25 cm piece can be used in the lower abdomen. It can be laced transversely, the vertical dimension 10 cm, can be positioned with the lower edge at level of the pubic symphsis, and the upper edge at the lower border of the umbilicus. The 25 cm transverse dimension can be suitable.
  • a second scaffold can be cut and tailored to use in the supra-umbilcal region, with care taken not to leave too close to the umbilical closure. As the closure around the umbilicus occasionally may not heal primarily, extra care is taken with sutures/device in this location.
  • the handling characteristics can be excellent.
  • the device is secured at its periphery with a 3-0 V-Lock (COVIDIEN brand of barbed suture, made of a material similar to PDS).
  • the patient can do very well and can be hospitalized overnight.
  • the patient has a total of 5, ten mm flat blake drains—two that drain the back and three in the front.
  • the patient stays on antibiotics until drains were which is typically within 10 to 20 days.
  • a device is a biocompatible, bioresorbable, pliable surgical matrix (mesh or scaffold) made preferably from the silk of the Bombyx mori silkworm. Because raw silk fibers are comprised of a fibroin protein core filament that is naturally coated with the antigenic globular protein sericin the sericin is removed by aqueous extraction. Yarn is then made from the sericin-depleted fibroin protein filaments by helical twisting to form a multi-filament protein fiber. The multi-filament protein fiber yarn is then knit into a three dimensional patterned matrix (mesh or scaffold) that can be used for soft tissue support and repair.
  • the device upon implantation provides immediate physical and mechanical stabilization of tissue defects because of its strength and porous construction. Additionally, the porous lattice design of the device facilitate native tissue generation (that is tissue ingrowth) and neovascularization.
  • the natural tissue repair process begins with deposition of a collagen network. This network integrates within the protein matrix, interweaving with the porous construct.
  • Neovascularization begins with endothelial cell migration and blood vessel formation in the developing functional tissue network. This new functional tissue network and its corresponding vascular bed ensure the structural integrity and strength of the tissue.
  • the device provides the majority of structural support.
  • the device (made of silk) is gradually deconstructed (bioresorbed) into its amino acid building blocks. The slow progression of the natural biological process of bioresorption allows for the gradual transition of support from the protein matrix of the device to the healthy native tissue thereby achieving the desired surgical outcome.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Textile Engineering (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Dermatology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Knitting Of Fabric (AREA)

Abstract

An implantable, pliable knitted silk mesh for use in human soft tissue support and repair having a particular knit pattern that substantially prevents unraveling and preserves the stability of the mesh when cut, the knitted mesh including at least two yarns laid in a knit direction and engaging each other to define a plurality of nodes.

Description

    CROSS REFERENCE
  • This patent application is a continuation of U.S. patent application Ser. No. 14/462,473, filed Aug. 18, 2014, which is a continuation in part of U.S. patent application Ser. No. 13/715,872, filed Dec. 14, 2012, which is a continuation in part of U.S. patent application Ser. No. 13/306,325, filed Nov. 29, 2011, which is a continuation in part of U.S. patent application Ser. No. 13/186,151, filed Jul. 19, 2011, which is a continuation in part of U.S. patent application Ser. No. 13/156,283, filed Jun. 8, 2011, which is a continuation in part of U.S. patent application Ser. No. 12/680,404, filed Sep. 19, 2011, which is a national stage entry of PCT patent application number PCT/U.S. 09/63717, filed Nov. 9, 2009, which claims priority to and the benefit of U.S. provisional patent application number 61/122,520, filed Dec. 15, 2008, all of which applications are expressly incorporated by reference herein in their entireties.
  • BACKGROUND
  • The present invention is a biodegradable (synonymously bioresorbable), biocompatible, pliable, knitted silk matrix, mesh or scaffold (the “device”) and methods for making and using the device in surgical and cosmetic procedures where soft tissue (i.e. a gland, organ, muscle, skin, ligament, tendon, cartilage, blood vessel or mesentery) support (through the load bearing function of the device) is desired, such as for example in breast reconstruction, breast augmentation, abdominal surgery, gastro-intestinal surgery, hernia repair and facial surgery. The soft tissue support can be provided by the device itself (for example in conjunction with a hernia repair) or by the device being used in conjunction with another implant, for example use of the device on or around a tissue expander or a breast implant used in a breast reconstruction or a breast augmentation surgical procedure.
  • Soft tissue support surgical meshes and scaffolds are known and are usually made of a synthetic polymer such as Teflon®, polypropylene, polyglycolic acid, polyester, or polyglactin 910. Biomaterials such a tissue based or tissue derived material, for example an acellular dermal matrix (“ADM”) obtained from human and animal derived dermis have also been used but do not have the mechanical integrity of high load demand applications (e.g. ligaments, tendons, muscle) or the appropriate biological functionality because most biomaterials either degrade too rapidly (e.g., collagen, PLA, PGA, or related copolymers) or are non-degradable (e.g., polyesters, metal), and in either case functional autologous tissue ingrowth (important to assist transfer of a load bearing function from an implanted biomaterial as the biomaterial is bioresorbed by the body) occurs very little or fails to occur. In certain instances a biomaterial may misdirect tissue differentiation and development (e.g. spontaneous bone formation, tumors) because it lacks biocompatibility with surrounding cells and tissue. As well, a biomaterial that fails to degrade typically is associated with chronic inflammation and such a response is detrimental to (i.e. weakens) surrounding and adjacent tissue.
  • Silk is a natural (non-synthetic) protein made of high strength fibroin fibers with mechanical properties similar to or better than many of synthetic high performance fibers. Silk is also stable at physiological temperatures in a wide range of pH, and is insoluble in most aqueous and organic solvents. As a protein, unlike the case with most if not all synthetic polymers, the degradation products (e.g. peptides, amino acids) of silk are biocompatible. Silk is non-mammalian derived and carries far less bioburden than other comparable natural biomaterials (e.g. bovine or porcine derived collagen). Silk, as the term is generally known in the art, means a filamentous fiber product secreted by an organism such as a silkworm or spider. Silks can be made by certain insects such as for example Bombyx mori silkworms, and Nephilia clavipes spiders. There are many variants of natural silk. Fibroin is produced and secreted by a silkworm's two silk glands. As fibroin leaves the glands it is coated with sericin a glue-like substance. Spider silk s produced as a single filament lacking the immunogenic protein sericin. Use of both silkworm silk and spider silk (from a natural source or made recombinantly) is within the scope of the present invention.
  • Silkworm silk has been used in biomedical applications. The Bombyx mori species of silkworm produces a silk fiber (a “bave”) and uses the fiber to build its cocoon. The bave as produced include two fibroin filaments or broins which are surrounded with a coating of the gummy, antigenic protein sericin. Silk fibers harvested for making textiles, sutures and clothing are not sericin extracted or are sericin depleted or only to a minor extent and typically the silk remains at least 10% to 26% by weight sericin. Retaining the sericin coating protects the frail fibroin filaments from fraying during textile manufacture. Hence textile grade silk is generally made of sericin coated silk fibroin fibers. Medical grade silkworm silk is used as either as virgin silk suture, where the sericin has not been removed, or as a silk suture from which the sericin has been removed and replaced with a wax or silicone coating to provide a barrier between the silk fibroin and the body tissue and cells. Physicians prefer and require an implantable, knitted silk medical device with the flexibility to be stretched, expanded, pulled into shape, elongated and/or draped into place over, around or under soft tissue or an implant at the time of a soft tissue surgical or medical procedure, without the silk medical device upon its elongation breaking, splitting or unraveling. Thus there is a need for such a pliable, sericin extracted implantable, bioresorbable silk medical device.
  • SUMMARY
  • A device according to the present invention fulfills this need. The device in one embodiment is a pliable. knitted mesh having at least two yarns laid in a knit direction and engaging each other to define a plurality of nodes, the at least two yarns including a first yarn and a second yarn extending between and forming loops about two nodes, the second yarn having a higher tension at the two nodes than the first yarn, the second yarn substantially preventing the first yarn from moving at the two nodes and substantially preventing the knitted mesh from unraveling at the nodes. The device is a surgical mesh made of silk that is knitted, multi-filament, and bioengineered. It is mechanically strong, biocompatible, and long-term bioresorbable. The sericin-extracted silkworm fibroin fibers of the device retain their native protein structure and have not been dissolved and/or reconstituted.
  • “Bioresorbed” means that none or fewer than 10% of the silk fibroin fibers of the device can be seen to the naked (no magnification aid) eye upon visual inspection of the site of implantation of the device or of a biopsy specimen therefrom, and/or that the device is not palpable (i.e. cannot be felt by a surgeon at a time after the surgery during which the device was implanted) upon tactile manipulation of the dermal location of the patient at which the device was implanted. Typically either or both of these bioresorbed determinants occur about 1 to about 5 years are in vivo implantation of the device.
  • “About” means plus or minus ten percent of the quantify, number, range or parameter so qualified.
  • The device of the present invention is a pliable, sterile surgical mesh or scaffold available in a variety of shapes and sizes ready for use in open surgical or in laparoscopic procedures. The device is flexible and well-suited for delivery through a laparoscopic trocar due to its strength, tear resistance, suture retention, and ability to be cut in any direction. The device can provide immediate physical and mechanical stabilization of a tissue defect through the strength and porous (scaffold-like) construction of the device. The device can be used as a transitory scaffold for soft tissue support and repair to reinforce deficiencies where weakness or voids exist that require the addition of material to obtain the desired surgical outcome.
  • The device can comprise filament twisted silk yarns. The silk is made of silk fibroin fibers. The silk fibroin fibers are preferably sericin depleted or sericin extracted silk fibroin fibers. The device has an open pore knit structure. Significantly, after implantation the device and ingrown native tissue can maintain at least about 90% of the time zero device strength of the device at one month or at three months or at six months in vivo after the implantation. The device can be implanted without regard to side orientation of the device and the combined thickness of the device and ingrowth of native tissue scaffold increases with time in vivo in the patient.
  • As used herein, “fibroin” includes silkworm fibroin (i.e. from Bombyx mori) and fibroin-like fibers obtained from spiders (i.e. from Nephila clavipes). Alternatively, silk protein suitable for use in the present invention can be obtained from a solution containing a genetically engineered silk, such as from bacteria, yeast, mammalian cells, transgenic animals or transgenic plants. See, for example, WO 97/08315 and U.S. Pat. No. 5,245,012.
  • The device is a pliable, knitted silk fabric intended for implantation in a human body. The word “knit” is synonymous with the word “knitted”, so that a knit silk fabric is the same as a knitted silk fabric. The device can be a warp knit or can be weft knit silk fabric. Preferably, the device according of the present invention is a pliable, biocompatible, warp knit, multi-filament silk fabric. A woven material or fabric is made by weaving, which is a process that does not use needles, and results in a fabric with different characteristics. In particular, a woven fabric is made by a non-needle process using multiple yarns that interlace each other at right angles to form a structure wherein one set of yarn is parallel to the direction of fabric formation. Woven fabrics are classified as to weave or structure according to the manner in which warp and weft cross each other. The three main types of weaves (woven fabrics) are plain, twill, and satin. Woven (weaved) silk fabric, woven textiles and woven fabrics are not within the scope of the present invention. Non-woven fabrics are also not within the scope of the present invention. Non-woven (also refer to as bonded) fabrics are formed by having multiple fibers cohered together chemically or physically, without use of needles.
  • Unlike the excluded woven and non-woven materials, a knitted fabric is generally softer and more supple because its thread is treated differently. Thus a knitted fabric is made by using needles (such as for example the needles of a single or double bed knit machine) to pull threads up through the preceding thread formed into a loop by the needle. Because a knitted fabric is made using needles the knitted fabric can have one or multiple yarn intermeshing (also referred as interloping). Preferably, the device is made of biodegradable silk and is a biocompatible, non-woven, knit, multi-filament silk fabric or mesh.
  • Embodiments according to aspects of the present invention provide a biocompatible surgical silk mesh device for use in soft or hard tissue repair. Examples of soft tissue repair include hernia repair, rotator cuff repair, cosmetic surgery, implementation of a bladder sling, or the like. Examples of hard tissue repair, such as bone repair, involve reconstructive plastic surgery, ortho trauma, or the like.
  • Advantageously, the open structure of the device allows tissue ingrowth as the silk forming the device is bioresorbed, at a rate permitting smooth transfer of mechanical properties to the new tissue from the device. Furthermore, the device has a knit pattern that substantially or entirely prevents unraveling, especially when the device is cut. The device have a stable knit pattern made by knitting silk yarn with variations of tension between at least two yarns laid in a knit direction. For example, a first yarn and a second yarn may be laid in a knit direction to form “nodes” for a mesh device. The knit direction for the at least two yarns, for example, may be vertical during warp knitting or horizontal during weft knitting. The nodes of a mesh device, also known as intermesh loops, refer to intersections in the mesh device where the two yarns form a loop around a knitting needle. In some embodiments, the first yarn is applied to include greater slack than the second yarn, so that, when a load is applied to the mesh device, the first yarn is under a lower tension than the second device. A load that places the at least two yarns under tension may result, for example, when the mesh device is sutured or if there is pulling on the mesh device. The slack in the first yarn causes the first yarn to be effectively larger in diameter than the second yarn, so that the first yarn experiences greater frictional contact with the second yarn at a node and cannot move, or is “locked,” relative to the second yarn. Accordingly, this particular knit design may be referred to as a “node-lock” design.
  • The device bioresorbs at a rate sufficient that allows tissue in-growth while transferring the load-bearing responsibility to the native tissue. An embodiment of the device can be made from Bombyx mori silkworm silk fibroin or from spider silk. The raw silk fibers have a natural globular protein coating known as sericin, which may have antigenic properties and must be depleted before implantation. Accordingly, the yarn is taken through a depletion process as described, for example, by Gregory H. Altman et al., “Silk matrix for tissue engineered anterior cruciate ligaments,” Biomaterials 23 (2002), pp. 4131-4141, the contents of which are incorporated herein by reference. As a result, the silk material used in the device embodiments contains substantially no (less than 5%) sericin.
  • A process for making the pliable, knitted silk mesh (and for obtaining the mesh) can have the steps of: knitting a first silk yarn in a first wale direction using the knit pattern 3/1-1/1-1/3-3/3; knitting a second silk yarn in a second wale direction using the knit pattern 1/1-1/3-3/3-3/1; knitting a third silk yarn in a first course direction using the knit pattern 3/3-3/3-5/5-5/5-3/3-3/3-5/5-5/5-1/1-1/1-5/5-5/5-3/3-3/3-5/5-5/5-3/3-3/3-7/7-7/7, and; knitting a fourth silk yarn in a second course direction using the knit pattern 1/1-5/5-5/5-3/3-3/3-5/5-5/5-3/3-3/3-7/7-7/7-3/3-3/3-5/5-5/5-3/3-3/3-5/5-5/5-1/1, thereby obtaining the pliable knitted silk mesh. In this process the two movements in the wale direction occur on separate needle beds, with alternate yarns, and with loops formed on the course movements staggered within the repeat knit pattern. In this process of claim 1 the silk yarns can be made of a nine filament, twisted, and sericin depleted silk fibers, and the yarns can be made with three ends of Td 20/22 raw silk twisted together in the S direction to form a ply with 20 tpi and further combining 3 of the resulting ply with 10 tpi in the Z direction. Additionally, the e stitch density or pick count for silk mesh design can be about 40 picks per centimeter including the total picks count for the technical front face and the technical back face of the mesh, or equivalently about 20 picks per cm considering only one face of the mesh.
  • A detailed process for making the pliable knitted silk mesh, the process can have the steps of: knitting a first silk yarn in a first wale direction using the pattern 3/1-1/1-1/3-3/3; knitting a second silk yarn in a second wale direction using the pattern 1 /1-1/3-3/3-3/1; knitting a third silk yarn in a first course direction using the pattern 3/3-3/3-5/5-5/5-3/3-3/3-5/5-5/5-1/1-1/1-5/5-5/5-3/3-3/3-5/5-5/5-3/3-3/3-7/7-7/7, and; knitting a fourth silk yarn in a second course direction using the pattern 1/1-5/5-5/5-3/3-3/3-5/5-5/5-3/3-3/3-7/7-7/7-3/3-3/3-5/5-5/5-3/3-3/3-5/5-5/5-1/1, wherein: the two movements in the wale direction occur on separate needle beds with alternate yarns and loops that occur on every course are staggered within repeat; the silk yarns are made of a nine filament, twisted, and sericin depleted silk fibers; the yarns are made with 3 ends of Td 20/22 ra(g) w silk twisted together in the S direction to form a ply with 20 tpi and further combining 3 of the resulting ply with 10 tpi in the Z direction, and; the stitch density or pick count for silk mesh design is 40 picks per centimeter including the total picks count for the technical front face and the technical back face of the mesh, or equivalently 20 picks per cm considering only one face of the mesh, thereby obtaining the pliable knitted silk mesh.
  • The pliable, knitted silk mesh can have percent elongation at break of between about 4% or 32% to about 109% or 110%, a burst strength of about 0.45 MPa, and a stiffness of about 25 N/mm.
  • A process for making a pliable, knitted silk mesh, the process comprising the steps of: knitting a first silk yarn in a first wale direction using the knit pattern 3/1-1/1-1/3-3/3; knitting a second silk yarn in a second wale direction using the knit pattern 1/1-1/3-3/3-3/1, knitting a third silk yarn in a first course direction using the knit pattern 3/3-3/3-5/5-5/5-3/3-3/3-5/5-5/5-1/1-1/1-5/5-5/5-3/3-3/3-5/5-5/5-3/3-3/3-7/7-7/7, and; knitting a fourth silk yarn in a second course direction using the knit pattern 1/1-5/5-5/5-3/3-3/3-5/5-5/5-3/3-3/3-7/7-7/7-3/3-3/3-5/5-5/5-3/3-3/3-5/5-5/5-1/1,thereby obtaining the pliable knitted silk mesh. Additionally, in this just set forth process in this paragraph: (a) the two movements in the wale direction occur on separate needle beds (a knitting machine having two needle beds); and (b) with alternate yarns such as they knit with the opposing needle bed to their location (the front set of yarn knit with the back needle bed and the back set of yarn knit with the front needle bed). Furthermore, in this just set forth in this paragraph process the silk yarns are made of a nine filaments (“filaments” can be defined as raw silk yarn having a finesse of about Td 20/22) of twisted, and sericin depleted silk fibers. Finally, in this just set forth in this paragraph process the yarns are made with three ends of raw silk yarn twisted together having a finesse of Td 20/22 twisted together in the S direction (clockwise direction of twist) to form a ply with 20 tpi (twist per inch is the number of twist measured in an inch of yarn) and further combining 3 of the resulting ply with 10 tpi in the Z direction(counter clockwise direction of twist), and the stitch density or pick count for silk mesh design is about 40 picks per centimeter including the total picks count for the technical front face and the technical back face of the mesh, or equivalently about 20 picks per cm considering only one face of the mesh.
  • Our invention also includes a process for making a pliable knitted silk mesh, the process comprising the steps of: knitting a first silk yarn in a first wale direction using the pattern 3/1-1/1-1/3-3/3; knitting a second silk yarn in a second wale direction using the pattern 1/1-1/3-3/3-3/1, knitting a third silk yarn in a first course direction using the pattern 3/3-3/3-5/5-5/5-3/3-3/3-5/5-5/5-1/1-1/1-5/5-5/5-3/3-3/3-5/5-5/5-3/3-3/3-7/7-7/7, and; knitting a fourth silk yarn in a second course direction using the pattern 1/1-5/5-5/5-3/3-3/3-5/5-5/5-3/3-3/3-7/7-7/7-3/3-3/3-5/5-5/5-3/3-3/3-5/5-5/5-1/1, wherein: (e) the two movements in the wale direction occur on separate needle beds with alternate yarns and loops that occur on every course are staggered within repeat; (f) the silk yarns are made of a nine filament, twisted, and sericin depleted silk fibers; (g) the yarns are made with 3 ends of Td 20/22 raw silk twisted together in the S direction to form a ply with 20 tpi and further combining 3 of the resulting ply with 10 tpi in the Z direction, and (h) the stitch density or pick count for silk mesh design is 40 picks per centimeter including the total picks count for the technical front face and the technical back face of the mesh, or equivalently 20 picks per cm considering only one face of the mesh, thereby obtaining the pliable knitted silk mesh.
  • Our invention also includes a pliable knitted silk mesh made by: knitting a first silk yarn in a first wale direction using the pattern 3/1-1/1-1/3-3/3; knitting a second silk yarn in a second wale direction using the pattern 1/1-1/3-3/3-3/1, knitting a third silk yarn in a first course direction using the pattern 3/3-3/3-5/5-5/5-3/3-3/3-5/5-5/5-1/1-1/1-5/5-5/5-3/3-3/3-5/5-5/5-3/3-3/3-7/7-7/7, and; knitting a fourth silk yarn in a second course direction using the pattern 1/1-5/5-5/5-3/3-3/3-5/5-5/5-3/3-3/3-7/7-7/7-3/3-3/3-5/5-5/5-3/3-3/3- 5/5-5/5-1/1. With this pliable knitted silk mesh of the two movements in the wale direction occur on separate needle beds with alternate yarns and loops that occur on every course are staggered within repeat, and; the silk yarns are made of a nine filament, twisted, and sericin depleted silk fibers, and; the yarns are made with 3 ends of Td 20/22 raw silk twisted together in the S direction to form a ply with 20 tpi and further combining 3 of the resulting ply with 10 tpi in the Z direction, and; the stitch density or pick count for silk mesh design is 40 picks per centimeter including the total picks count for the technical front face and the technical back face of the mesh, or equivalently 20 picks per cm considering only one face of the mesh.
  • Our invention also includes a pliable knitted silk mesh made by: knitting a first silk yarn in a first wale direction using the pattern 3/1-1/1-1/3-3/3; knitting a second silk yarn in a second wale direction using the pattern 1/1-1/3-3/3-3/1, knitting a third silk yarn in a first course direction using the pattern 3/3-3/3-5/5-5/5-3/3-3/3-5/5-5/5-1/1-1/1-5/5-5/5-3/3-3/3-5/5-5/5-3/3-3/3-7/7-7/7, and; knitting a fourth silk yarn in a second course direction using the pattern 1/1-5/5-5/5-3/3-3/3-5/5-5/5-3/3-3/3-7/7-7/7-3/3-3/3-5/5-5/5-3/3-3/3- 5/5-5/5-1/1, wherein: (e) the two movements in the wale direction occur on separate needle beds with alternate yarns and loops that occur on every course are staggered within repeat; (f) the silk yarns are made of a nine filament, twisted, and sericin depleted silk fibers; (g) the yarns are made with 3 ends of Td 20/22 ra(g) w silk twisted together in the S direction to form a ply with 20 tpi and further combining 3 of the resulting ply with 10 tpi in the Z direction, and; (h) the stitch density or pick count for silk mesh design is 40 picks per centimeter including the total picks count for the technical front face and the technical back face of the mesh, or equivalently 20 picks per cm considering only one face of the mesh.
  • DRAWINGS
  • The present invention can be more fully understood from the detailed description and the accompanying drawings, which are not necessarily to scale, wherein:
  • FIG. 1A is a photograph of a pattern layout for a silk-based scaffold design in accordance with the present invention.
  • FIGS. 1B and 1C illustrate an example pattern layout for the scaffold design of FIG. 1A including all pattern and ground bars according to aspects of the present invention.
  • FIGS. 1D and 1E illustrate an example pattern layout for a double needle bed mesh or scaffold according to aspects of the present invention from FIG. 1B for ground bar # 4.
  • FIGS. 1F and 1G illustrate an example pattern layout for a double needle bed mesh or scaffold according to aspects of the present invention from FIG. 1B for pattern bar # 5.
  • FIGS. 1H and 1I illustrate an example pattern layout for a double needle bed mesh or scaffold according to aspects of the present invention from FIG. 1B for ground bar # 7.
  • FIG. 1J illustrates an example pattern simulation for a double needle bed mesh demonstrated in FIG. 1B according to aspects of the present invention.
  • FIG. 1K shows the yarn feed rates used during the knit process used to make the most preferred embodiment of the device within the scope of the present invention.
  • FIG. 2 illustrates the twisting and multi-ply nature of a yarn comprised of silk fibroin bundles as used in an embodiment of the present invention.
  • FIG. 3A shows a scanning electromicrograph (“SEM”) of native silk fibers.
  • FIG. 3B shows a SEM of sericin extracted silk fibers useful to make the device. The size bar at the top of each of FIG. 3A and FIG. 3B measures 20 microns.
  • FIG. 4 is a photograph of an embodiment (a knitted silk fabric ready for implantation) of a device within the scope of the present invention (placed above a millimeter ruler).
  • FIG. 5A is photograph at 16× magnification of a portion of the FIG. 4 embodiment.
  • FIG. 5B is photograph of the FIG. 4 embodiment showing the ease with which it can be cut without the fabric unraveling or fraying.
  • FIG. 6 is a photograph of a pattern layout for a silk-based scaffold design in accordance with the present invention (“the device” of Example 1)
  • FIG. 7 represents one of the element for the pattern layout making the device on a raschel knitting machine. 7A is the needle layout over two needle bed (front and back); 7B represent the yarn evaluation for the 4 bars making the device in FIG. 6; 7C is one of the grid equivalent to one needle space and one course (front or back of the pattern)
  • FIG. 8 represents one of the element for the pattern layout making the device on a raschel knitting machine. 8A is the threading sequence for the guide bar heddle, each color dot represent one heddle eyelet; 8B is the bar and devices numbering sequence.
  • FIG. 9 represents one of the element for the pattern layout making the device on a raschel knitting machine. 9A is the sequence for the movements making up the pattern bars; 9B is the sequence for the value making up the take down; 9C-9D-9E are the sequences for the feed rate of the yarn making up the pattern. The present invention is based on discovery of an implantable, bioresorbable, biocompatible, pliable, knitted, porous silk mesh (the “device”) which upon implantation provides soft tissue support and, as the device bioresorbs, transfer of its load bearing (support) function to new tissue formed at the site of implantation. The device is preferably made from Bombyx mori silkworm silk. It can also be made from spider silk, including recombinantly made spider silk. The preferred knit pattern of the device accomplishes variation in tension between yarns at the knit nodes (the yarn interlocking loops) thereby preventing unraveling of the mesh when cut for use in surgery. FIG. 5A (left hand side) shows a 16× magnification of the device knit pattern and FIG. 5B (right hand side) shows ease of cutting without fraying or unraveling.
  • Importantly, the device made according to the present invention allows significant and consistent tissue ingrowth while bioresorbing at a rate which permits smooth transfer of load bearing support to the newly formed tissue. Thus the device is made of a biocompatible silk protein that is eventually bioresorbed. The raw silk fibers obtained from Bombyx mori silkworms comprise a fibroin protein core filament coated with the antigenic globular protein sericin. The sericin is removed or substantially all removed by hot aqueous (i.e. soap) extraction (wash) leaving behind fibroin protein filament consisting of layers of antiparallel beta sheets which provide both stiffness and toughness. FIG. 3A is a SEM photograph of native (sericin coated) silk fibers, and FIG. 3B of the fibers after sericin extraction, as then used to make (knit) the device. The porous knit structure of the device so made is shown by FIGS. 1A, 4 and 5.
  • Multiple sericin-depleted fibroin protein fibers are combined and twisted together to form a multi-filament yarn. The multi-filament fibroin yarn is subsequently knitted into a three dimensional pattern to serve as soft tissue support and repair. The resulting device is mechanically strong, flexible, and tear-resistant. The device is a single use only scaffold that can be produced in a variety of shapes, sizes and thicknesses and can be terminally sterilized.
  • The device provides immediate physical and mechanical stabilization of tissue defects because of its strength and porous construction and is useful as a transitory scaffold for soft tissue support and repair. It provides reinforcement for deficiencies where weakness or voids exist that require additional material reinforcement to obtain the desired surgical outcome. The bioresorption process occurs over time after implantation of the device as tissue in-growth and neovascularization takes place.
  • The device can be used to assist soft tissue repair. Examples of soft tissue repair include breast reconstruction, hernia repair, cosmetic surgery, implementation of a bladder sling, or the like.
  • Silk is the material used to make the device. Particular embodiments may be formed from Bombyx Mori silkworm silk fibroin. As explained a preferred embodiment of the device is made using sericin extracted silk fibers with certain knit machine parameters or settings. A detailed explanation of the knit pattern and knit process used to make a most preferred embodiment of the present invention will now be set forth. FIG. 1A is a photograph of a pattern layout for a device (silk-based mesh or scaffold) in accordance with the present invention. FIG. 1A shows the wale direction 10 and the course direction 15 and placement of the silk yarns in either the wale 10 or course 15 scaffold material direction or location. The device is preferably formed on a raschel knitting machine such as Comez DNB/EL-800-8B set up in 10 gg needle spacing by the use of three movements as shown in pattern layout in FIGS. 1B and 1C: two movements in the wale direction, the vertical direction within the fabric, and one movement in the course direction, the horizontal direction of the fabric. The movements in the wale direction occur on separate needle beds with alternate yarns; loops that occur on every course are staggered within repeat. The yarn follows a repeat pattern of 3/1-1 /1-1 /3-3/3 for one of the wale direction movements as shown in FIGS. 1D and 1E and 1/1-1/3-3/3-3/1 for the other wale direction movement as shown in FIGS. 1H and 11. The interlacing of the loops within the fabric allows for one yarn to become under more tension than the other under stress, locking it around the less tensioned yarn, thereby keeping the fabric from unraveling when cut. The other movement in the course direction as shown in FIG. 1F and 1G occurs in every few courses creating the porous design of the device. These yarns follow a repeat pattern of 7/7-9/9-7/7-9/9-7/7-9/9/-1/1-1/1-3/3-1/1-3/3-1/1-3/3-1/1-3/3- 1/1 for the course direction movement. The pattern simulation layout of this pattern was rendered using ComezDraw 3 software in FIG. 1J considering a yarn design made with 3 ends of Td (denier count) 20/22 raw silk twisted together in the S direction to form a ply with 20 tpi (turns per inch) and further combining three of the resulting ply with 10 tpi. In FIG. 1J The same yarn design is used for the movements occurring in the wale and course directions. The stitch density or pick count for the design in FIG. 1J is 34 picks per centimeter considering the total picks count for the technical front face and the technical back face of the fabric, or 17 picks per cm considering only on the face of the fabric. The operating parameters described in FIGS. 1B to 1I are the optimum values for the specific yarn design used for the pattern simulation layout of FIG. 1J. In FIG. 1J item 17 is a simulated double needle bed mesh or scaffold. To further explain aspects shown by FIG. 1F: following standard terminology well known in the knit industry “F” means front and “B” means back and with regard to FIG. 1F shows the incremental sequence of pattern lines for the course direction. The numbers “12, 9, 6 and 3” at the bottom of FIG. 1F represent the number of needles in the needle bed starting count from left to right. The upwards pointing arrows near the bottom of FIG. 1F show the needle slots occupied by a needle actively engaged with the yarn for the knit machine/knit process. Rows 1F to 6B of FIG. 1F show the knit pattern used to make the device. The FIG. 1F rows 1F to 6B knit pattern is repeated 94 times to make a 25 cm sheet length of the fabric of the device, the number of repeats of the pattern being fewer or more if respectively a smaller or larger section of device fabric is desired to result from the knit process. The FIG. 1F rows 1F to 6B knit pattern is equivalently described by the above set forth, combined three knit movement: the first wale direction 3/1-1 /1-1 /3-3/3 knit pattern; the second wale direction 1/1-1/3-3/3-3/1 knit pattern, and; the course direction 7/7-9/9-7/7-9/9-7/7-9/9/-1/1-1/1-3/3-1/1-3/3-1/1 knit pattern. Rows 7F to 10B in FIG. 1F (and equivalently the terminal 3/3-1/1-3/3-1/1-3/3-1/1-3/3-1/1 portion of the course knit pattern) show the knit pattern used to make a spacer which creates a kitted area of fabric separation (i.e. a cut location) between adjacent 25 cm lengths of the knitted device fabric which is knitted by the process set forth above as one continuous sheet of fabric. The specific feed rates for the yarn forming this most preferred embodiment of the device is shown in FIG. 1K where column 17 shows the yarn feed rate used for the first wale direction 3/1-1 /1-1 /3-3/3 knit pattern. A rate of 212 is equivalent to 74.8 cm of yarn per 480 coursed or per rack. Column 23 of FIG. 1K reports the yarn feed rate that is used for the second wale direction 1/1-1/3-3/3-3/1 knit pattern, where again a rate of 212 is equivalent to 74.8 cm of yarn per 480 coursed or per rack. Column 22 of FIG. 1K shows the yarn feed rate that is used for the course direction 7/7-9/9-7/7-9/9-7/7-9/9/-1/1-1/1-3/3-1/1-3/3-1/1-3/3-1/1-3/3-1/1-3/3-1/1-3/3-1/1 knit pattern; a rate from line 1F to 6B of 190 is equivalent to 67.0 cm of yarn per 480 coursed or per rack, while a rate from line 7F to 10B of 90 is equivalent to 31.7 cm of yarn per 480 coursed or per rack. Column 21 of FIG. 1K shows that the yarn feed rate that is used for the second to last yarn at each edge of the knitted device fabric in the course direction 7/7-9/9-7/7-9/9-7/7-9/9/-1/1-1/1-3/3-1/1-3/3-1/1-3/3-1/1-3/3-1/1-3/3-1/1-3/3-1/1 knit pattern; a rate from line 1F to 6B of 130 is equivalent to 45.8 cm of yarn per 480 coursed or per rack, while a rate from line 7F to 10B of 90 is equivalent to 31.7 cm of yarn per 480 coursed or per rack. Column 20 of FIG. 1K reports (shows) the yarn feed rate that is used for the last yarn at each edge of the knitted device fabric in the course direction 7/7-9/9-7/7-9/9-7/7-9/9/-1/1-1/1-3/3-1/1-3/3-1/1-3/3-1/1-3/3-1/1-3/3-1/1-3/3-1/1 knit pattern; a rate from line 1F to 6B of 130 is equivalent to 45.8 cm of yarn per 480 coursed or per rack, while a rate from line 7F to 10B of 90 is equivalent to 31.7 cm of yarn per 480 coursed or per rack.
  • The knit pattern shown in FIG. 1A can be knit to any width depending upon the knitting machine and can be knitted with any of the gauges available with the various crochet machines or warp knitting machines. Table 1 outlines the device fabric widths that may be achieved using a different numbers of needles on different gauge machines. The dimensions in Table 1 are approximate due to the shrink factor of the knitted fabric which depends on stitch design, stitch density, and yarn size used.
  • TABLE 1
    Needle Knitting
    Count Width (mm)
    Gauge From To From To
    48 2 5656 0.53 2997.68
    24 2 2826 1.06 2995.56
    20 2 2358 1.27 2994.66
    18 2 2123 1.41 2993.43
    16 2 1882 1.59 2992.38
    14 2 1653 1.81 2991.93
    12 2 1411 2.12 2991.32
    10 2 1177 2.54 2989.58
    5 2 586 5.08 2976.88
  • The device was knit with 9-filament, twisted silk yarns. A yarn was made from three silk bundles, each of which was comprised of individual silk fibrils as illustrated in FIG. 2. The 9-filament yarns were knit into the surgical scaffold. The wales ran horizontally and the courses ran vertically along the scaffold.
  • A preferred embodiment of the device ready for surgical use has a thickness between about 0.6 mm and about 1.0 mm, a width of about 10 cm (±about 1 cm) and a length of about 25 cm (±about 3 cm). Additionally the device has pores with an average diameter greater than about 10,000 um2, a density of from about 0.14 mg/mm3 to about 0.18 mg/mm3 (as determined by dividing the mass of the device by its volume [thickness, width, and length multiplied together]), and is comprised of at least about 95% silk fibroin. Furthermore, the device has a burst strength of from about 0.54 MPa to about 1.27 MPa, and a stiffness of between about 30N/mm to about 50 N.mm (the latter two mechanical properties of the preferred device determined by American Society for Testing and Materials D3787-07, “Standard Method for Burst Strength of Textiles: Constant Rate of Transverse Ball Burst Test” or ASTM F2150-07 Standard Guide for Characterization and Testing of Biomaterial Scaffolds Used in Tissue Engineered Medical Products)
  • The density of the device was calculated using the equation:
  • Material Density = Mass [ mg ] ( Average Length [ mm ] ) × ( Average Width [ mm ] ) × ( Thickness [ mm ] )
  • The cross-sectional area of full pores of the scaffold was measured using a microscope with sufficient magnification and image capture capability. The magnification was selected based upon the resolution of the pores in the knit pattern being examined.
  • Ball Burst Testing—Per ASTM D3787-07, each device tested was compressed between the two circular fixation brackets of the mechanical testing equipment, while leaving exposed a circular area of the test article that covers the radius of the inner fixture diameter. The sample device was secured with a constant fixation bolt torque to the locking nuts of the burst jig. Care was taken to ensure that the knit structure of the sample was organized and not skewed or sheared. The sample remained taut within the fixation brackets with equal distribution of tension. The ball burst fixture was attached to the mechanical testing equipment with a calibrated load cell. For the burst test, the fixture ball was inserted through the center diameter of the fixation brackets with a uniform pressure applied to the test article. The ball was inserted at a constant rate until the scaffold fails.
  • Burst stiffness was calculated by determining the slope of the middle 60% of the linear region of the compressive load vs. extension curve.
  • Maximum burst strength was calculated using the equation:
  • Maximum Burst Strength [ MPa ] = [ Maximum Burst Load [ N ] Exposed Area [ m 2 ] ] × 10 - 6
  • The exposed area was the circular area of the test article covering the radius (r) of the inner fixture diameter and was calculated using the equation below.

  • Exposed Area=πr 2
  • Tensile Testing—The tensile strength and elongation of the device were measured in accordance with ASTM D5035. Device samples were clamped in the mechanical test equipment. The upper clamp was mounted to the load cell, which was attached to the actuator and the lower clamp was mounted to the support plate. The lower limit of the actuator was set so that the upper and lower clamps were prevented from colliding. The upper clamp was aligned to make the faces of both clamps parallel to each other. The height of the mechanical equipment crosshead was adjusted so that the actuator was positioned to allow for a defined amount of upward movement and a specific sample gauge length resided between the upper and lower sample clamps.
  • The device was loaded by clamping the first 10 mm of the sample into the upper clamp and allowing the remainder of the sample to fall unrestrained into the bottom clamp opening. The last 10 mm of the sample was held by the bottom clamp. Care was taken to avoid pre-staining the device sample. Once the sample was clamped the actuator height was adjusted so that the sample had a pre-load of 2N. The actuator position was adjusted to achieve a specific gauge length and then reset to the zero-position at this point. The device sample was strained until it experienced ultimate tensile failure. The average maximum tensile strength, maximum tensile stress, percent elongation at break, and the tensile stiffness were determined. Tensile stiffness was calculated by determining the slope of the trend line of the linear portion of the tensile load vs. elongation curve bound by an upper and lower tensile load.
  • Tensile stiffness was calculated as the slope of the linear portion of the load verses elongation curve. The average maximum tensile strength, maximum tensile stress, linear stiffness, and percent elongation at break were determined.
  • Maximum tensile stress was calculated using the equation:
  • Maximum Tensile Stress [ MPa ] = [ Maximum Tensile Strength [ N ] Width [ m ] × Thickness [ m ] ] × 10 - 6
  • Whereby, the thickness and width were provided by the respective device sample thickness and width measurements.
  • Percent elongation at break was determined using the equation:
  • PercentElongationatBreak [ % ] = [ Elongation at Break [ mm ] Length [ mm ] ] %
  • Whereby, length was provided by the respective device sample length measurement.
  • Tear testing—A device sample with a width that is two-thirds that of the length was cut from each device. Before the samples are incubated in phosphate buffered saline, a small cut that was one-fourth the size of the sample width was made in the center of the device sample perpendicular to the length (through a single row of wales). Mechanical test equipment was used to measure the maximum tear resistance load. Clamps were inserted in the equipment. The upper clamp was mounted to the load cell that was attached to the actuator and the lower clamp was mounted to the base support plate. The lower limit of the actuator was set so that the upper and lower clamps were prevented from colliding. The upper clamp was aligned to make the faces of both clamps parallel to each other. The height of the mechanical equipment crosshead was adjusted so that the actuator was positioned to allow for a defined amount of upward movement and a specific sample gauge length resided between the upper and lower clamps. The device sample was placed in the upper clamp. The top 10 mm of the sample was covered by the clamp. The device sample was positioned so that the cut was located on the left side. The sample was aligned perpendicular with the clamp before the clamp was closed. The bottom portion of the sample was allowed to fall unrestrained into the bottom clamp opening. The clamp was closed and the sample was preloaded with 3N. The sample was strained at a constant rate until the sample tore at the cut point. From the resulting data the maximum tear resistance load was obtained.
  • Embodiments of the device according to the present invention can be knitted on a fine gauge crochet knitting machine. A non-limiting list of crochet machines capable of manufacturing the surgical mesh according to aspects of the present invention are provided by: Changde Textile Machinery Co., Ltd.; Comez; China Textile Machinery Co., Ltd.; Huibang Machine; Jakkob Muller AG; Jingwei Textile Machinery Co., Ltd.; Zhejiang Jingyi Textile Machinery Co., Ltd.; Dongguan Kyang the Delicate Machine Co., Ltd.; Karl Mayer; Sanfang Machine; Sino Techfull; Suzhou Huilong Textile Machinary Co., Ltd.; Taiwan Giu Chun Ind. Co., Ltd.; Zhangjiagang Victor Textile; Liba; Lucas; Muller Frick; and Texma.
  • Embodiments of the device according to the present invention can be knitted on a fine gauge warp knitting machine. A non-limiting list of warp knitting machines capable of manufacturing the surgical mesh according to aspects of the present invention are provided by: Comez; Diba; Jingwei Textile Machinery; Liba; Lucas; Karl Mayer; Muller Frick; Runyuan Warp Knitting; Taiwan Giu Chun Ind.; Fujian Xingang Textile Machinery; and Yuejian Group.
  • Embodiments of the device according to the present invention can be knitted on a fine gauge flat bed knitting machine. A non-limiting list of flat bed machines capable of manufacturing the surgical mesh according to aspects of the present invention are provided by: Around Star; Boosan; Cixing Textile Machine; Fengshen; Flying Tiger Machinary; Fujian Hongqi; G & P; Görteks; Jinlong; JP; Jy Leh; Kauo Heng Co., Ltd.; Matsuya; Nan Sing Machinery Limited; Nantong Sansi Instrument; Shima Seiki; Nantong Tianyuan; and Ningbo Yuren Knitting.
  • A test method was developed to check the cutability of the device formed according to aspects of the present invention. In the test method the device evaluated according to the number of scissor strokes needed to cut the device with surgical scissors. The mesh was found to cut excellently because it took only one scissor stroke to cut through it. The device was also cut diagonally and in circular patterns determining that the device did not unraveled once cut in either or both its length and width directions (see FIG. 5B). To determine further if the device would unravel a suture was passed through the closest pore from the cut edge, and pulled. This manipulation did not unravel the device. Thus the device was easy to cut and did not unravel after manipulation.
  • A device according to the present invention has been found to bioresorb by 50% in approximately 100 days after implantation, that is at least about 50% of the mass of the device bioresorbs after about 100 days after implantation in a human patient.
  • Physical properties of the device include thickness, density and pore sizes. The thickness of the device was measured utilizing a J100 Kafer Dial Thickness Gauge. A Mitutoyo Digimatic Caliper was used to find the length and width of the samples; used to calculate the density of the device. The density was found by multiplying the length, width and thickness of the mesh then dividing the resulting value by the mass. The pore size of the device was found by photographing the mesh with an Olympus SZX7 Dissection Microscope under 0.8× magnification. The measurements were taken using ImagePro 5.1 software and the values were averaged over several measurements. Physical characteristics of sample meshes, and two embodiments of the device are shown in Table 2.
  • TABLE 2
    Physical Characterization
    Thickness Pore Size Density
    Sample (mm) (mm2) (g/cm3)
    Mersilene Mesh 0.31 ± 0.01 0.506 ± 0.035 0.143 ± 0.003
    Bard Mesh 0.72 ± 0.00 0.465 ± 0.029 0.130 ± 0.005
    Vicryl Knitted Mesh 0.22 ± 0.01 0.064 ± 0.017 0.253 ± 0.014
    Device knit on a 1.00 ± 0.04 0.640 ± 0.409 0.176 ± 0.002
    single needle bed
    machine
    Device knit on a  0.89 ± 0.003  1.26 ± 0.400 ±0.005
    double needle bed
    machine
  • EXAMPLE 1 Pliable Silk Medical Device
  • We developed a pliable silk medical device (“the device” in Examples 1-6) and methods for making the device. By pliable it is meant that the device can stretched to increase its length and/or its width by between about 4% to about 110% before breaking (see Table 5 below). The device is a pliable, knitted, biocompatible silk scaffold device that can be implanted in a surgical procedure to provide soft tissue repair and soft tissue support, including to support an implant such as a breast implant or a tissue expander. Examples of soft tissue repair surgical procedures include breast reconstruction, hernia repair, cosmetic surgery, and implementation of a bladder sling. Although the device can employ a variety of polymer materials, preferable the device is made of silk, such as Bombyx Mori silkworm silk fibroin. The raw silk fibers used to make the device have a natural globular protein coating known as sericin, which may have antigenic properties and must be depleted before implantation of the device. Accordingly, yarn used to make the device is taken through a sericin depletion process as described in Altman et al., “Silk matrix for tissue engineered anterior cruciate ligaments,” Biomaterials 23 (2002), pp. 4131-4141, the contents of which are incorporated herein by reference in its entirety. After the depletion process the silk material used in the device embodiments contains substantially no sensitizing agents.
  • The device is preferably made by knitting sericin depleted silk yarn to form a porous mesh or fabric. The knitting can be carried out as raschel knitting, warp knitting and weft knitting. After being knitted the fabric of the device can be treated to enhance one or more device characteristics. The device treatment can be a finishing or surface coating process which can increase device hydrophilicity, biocompatibility and mechanical properties, such as handling for ease of cutting and graft pull-through, as well as add an anti-microbial or anti-fungal coatings. Specific examples of device surface treatments can include:
      • plasma modification
      • protein such as but not limited to fibronectin, denatured collagen or gelatin, collagen gels and
      • hydrophobic by covalent link or other chemical or physical method
      • peptides with hydrophilic and a hydrophobic end
      • peptides contain one silk-binding sequence and one biologically active\
      • sequence
      • biodegradable cellulose
      • surface sulfonation
      • ozone gas treatment
      • physically bound and chemically stabilized peptides
      • DNA/RNA aptamers
      • Peptide Nucleic Acids
      • Avimers
      • modified and unmodified polysaccharide coatings
      • carbohydrate coating
      • anti-microbial coatings
      • anti-fungal coatings phosphorylcholine coatings
  • As shown in Table 3 devices of varying width were made using different numbers of needles (needle count) on different gauge knitting machines. The device can be knit to any width limited by the knitting machine width and could be knitted with any of the gauges available with the various warp knitting machine.
  • TABLE 3
    Gauge Needle Count Knitting Width (mm)
    48 2-5,656 0.53-2,997.68
    24 2-2,826 1.06-2,995.56
    20 2-2,358 1.27-2,994.66
    18 2-2,123 1.41-2,993.43
    16 2-1,882 1.59-2,992.38
    14 2-1,653 1.81-2,991.93
    12 2-1,411 2.12-2,991.32
    10 2-1,177 2.54-2,989.58
    5 2-586   5.08-2,976.88
  • Embodiments of a prosthetic device according to our invention can be knitted on a fine gauge warp knitting machine. The following is a list of warp knitting machines capable of manufacturing the device: Comez; Diba; Jingwei Textile Machinery; Liba; Lucas; Karl Mayer; Muller Frick; Runyuan Warp Knitting; Taiwan Giu Chun Ind.; Fujian Xingang Textile Machinery; and Yuejian Group.
  • Embodiments of the device were knitted on a COMEZ DNB/EL-800-8B/P−20 warp knitting machine in 20 gauge with stroke for each of the positions from 1 through 30 as shown in Table 4.
  • TABLE 4
    Maximum stroke (mm)
    Position per pattern line
    1-8 1.25-60.00
     9 0.33-1.00 
    11-29 0.01-38.65
    30 0.33-1.00 
  • Our device has deformation properties that can be controlled by varying parameters within the device design, as set forth below to achieve desired device deformation (“i.e. pliable”) properties. A preferred and desired deformation property is the ability of the knitted device to exhibit at least about a 30-35% extension of its length in the machine direction and at least about 25-30% extension of its length in the cross direction without breaking or unraveling. These device properties are desired because they provide stretch or pliability for the physician user at the time of device implantation, therefor permitting the user to alter the device dimensions at the time of device implantation.
  • FIG. 6 is a photograph of an embodiment of a pattern layout for the device, showing a silk-based scaffold design. In FIG. 6 item A is a hexagonal or diamond shaped pore device each with a square area of about 4 square millimeters, other shape configuration may be designed such as round or polygonal as well as a different square area value. This device is preferably created on a raschel knitting machine such as Comez DNB/EL-800-8B-P set up in 10 gg needle spacing by the use of four movements as shown by the pattern layout in FIG. 7 and FIG. 8 and FIG. 9 with two movements in the wale direction, the vertical direction within the fabric, and two movements in the course direction, the horizontal direction of the fabric.
  • The movements in the wale direction occur on separate needle beds with alternate yarns; loops that occur on every course are staggered within repeat. While being knit the yarn follows a repeat pattern of 3/1-1 /1-1 /3-3/3 for one of the wale direction movements and 1/1-1/3-3/3-3/1 for the other wale direction movement, with each number representing a position, each “I” representing a guide bar movement, and each “-” representing a course (or stitch). For example, a yarn following a pattern of 3/1-1/1-1/3-3/3 would start in position 3 (located between the second and third needle slots) and move, as indicated by the “I”, to position 1. The knitting needles would form a stitch (as indicated by the “-”), remain in position 1 (since 1/1 represents no movement), form another stitch, move from position 1 to position 3, form another stitch, and then remain in position 3 (since 3/3 would also represent no movement). The pattern would repeat for the full length of the fabric. The same notation method can be applied to all stitch patterns and on all guide bars listed.
  • The interlacing of the loops within the fabric of the device as it is being knit allow for one yarn to be under more tension than the other under stress, locking it around the less tensioned yarn; keeping the fabric from unraveling when cut. One of the other two movements in the course direction occurs in every few courses creating the porous design of the scaffold. As being knit these yarns follow a repeat pattern of 3/3-3/3-5/5-5/5-3/3-3/3-5/5-5/5-1/1-1/1-5/5-5/5-3/3- 3/3-5/5-5/5-3/3-3/3-7/7-7/7 for the course direction movement. The other movements in the course direction occur in every few courses creating the openings in the scaffold. These yarns follow a repeat pattern of 1 /1-5/5-5/5-3/3-3/3-5/5-5/5-3/3-3/3-7/7-7/7-3/3-3/3-5/5-5/5-3/3-3/3-5/5-5/5-1 /1 for the course direction movement. The pattern adopts a yarn design made with 3 ends of Td 20/22 raw silk twisted together in the S direction to form a ply with 20 tpi and further combining 3 of the resulting ply with 10 tpi in the Z direction. The same yarn design is used for the movements occurring in the wale and course directions. The stitch density or pick count for the scaffold design is preferably 40 picks per centimeter including the total picks count for the technical front face and the technical back face of the fabric, or equivalently 20 picks per cm considering only one face of the fabric. The operating parameters are not limited to those described but just the optimum values for the physical properties of the device as a mesh or scaffold with the knit structure set forth which includes a twisted yarn. Sericin is preferably removed from the silk fibroin fibers after the yarn is formed (that is after the silk fibroin fibers have been twisted together, but not yet knitted) but before the mesh has been knit and/or after the device has been knitted. A preferred embodiment of the device is made of a 9 filament, twisted, and purified (sericin depleted) silk fiber. Once so formed into yarn (made from the twisted silk fibroin fibers) the yarn is then warp knitted as set forth above to thereby make the device. The properties of the device (mesh) include improved drapability, stretch, and conformability as compared to SERI standard 102 (SERI Surgical Scaffold), as shown in Table 5 below, where “SERI Standard 102” is the known SERI® Surgical Scaffold, and “SERI Pliable Sterilized” is the present device.
  • TABLE 5
    SERI Pliable
    Test Parameter SERI Standard 102 Sterilized
    Burst Stiffness (N/mm) 41(1) 25(3)  
    % Elongation @ break- FF 51(1) 109(2)  
    % Elongation @ break- FW 33(1)  81.36(2)
    % Elongation @ 16 N- FF   6.8(2) 33.3(2)
    % Elongation @ 16 N- FW   3.9(2) 32.1(2)
    (1)n = 4 devices average
    (2)n = 20 devices average
    (3)n = 15 devices average
  • The Table 5 properties were achieved, in part, by creating a symmetrical, diamond shaped pore that allows for bidirectional stretch. Selected further physical properties of an embodiment of the device are shown by Table 6.
  • TABLE 6
    Test Parameter Mean
    Burst Strength (MPa) 0.45(1)
    Stiffness (N/mm) 25.65(2)
    Tensile Stress- FF 6.61(1)
    % elongation @ break- FF 109.26(1)
    Tensile Stress- FW 2.86(1)
    % elongation @ break- FW 81.36(1)
    Tear Strength (N)- FF 148.86(1)
    Tear Strength (N)- FW 83.72(1)
    SPO force N/suture FF 16.98(1)
    SPO force N/suture FW 19.57(1)
    % Elongation @ 16 N- FF 33.32(1)
    % Elongation @ 32 N- FF 44.44(1)
    % Elongation @ 16 N- FF 32.17(1)
    % Elongation @ 32 N- FF 41.95(1)
    Density (mg/mm) 0.13(1)
    (1)n = 20 devices
    (2)n = 15 devices
    Table Legend
    MPa means Mega Pascal
    N/mm means Newton per millimeter
    FF means fabric formation (fabric length)
    FW means fabric width
    N means Newton
    mg/mm means milligram per millimeter.
  • EXAMPLE 2 Use of Pliable Silk Device in Two Stacie Breast Reconstruction
  • The pliable silk device of Example 1 (“the device”) can be used as a transitory scaffold for soft tissue support and repair in two-stage breast reconstruction to reinforce deficiencies where weakness or voids existed that required the addition of material to obtain the desired surgical outcome. The device is supplied sterile in a with one device utilized per breast. The device placed during each subject's stage I breast reconstruction with a tissue expander placement procedure. Following mastectomy (either immediate or delayed), the surgical site is readied for subpectoral tissue expander insertion in accordance with standard surgical methods. The tissue expander is rinsed in antibiotic solution (according to standard of care) and inserted into the subpectoral pocket. The device s cut to size (prior to, during, and/or after suturing) to repair the void between the pectoral muscle and the chest wall (i.e., inframammary fold region). The device is rinsed with antibiotic solution and sutured in place, with a minimum suture bite of 3 mm or one full row of material. If any cutting is performed in situ, rinsing of the implant site is performed. Intra-operative photography is taken of the device prior to closure. The tissue expander is filled as appropriate, drains placed according to usual standard of care and number and location of drain(s) noted. Standard rinsing of the surgical site and closure is performed. Prophylactic antibiotic use and duration is documented.
  • In a second surgical procedure, the tissue expander is removed and replaced with a breast implant. The surgical approach used to remove the tissue expander. Implant placement is subpectoralis muscle and the pocket is prepared. The breast implant is rinsed in antibiotic solution and positioned within the pocket. Closure is performed.
  • The device provides soft tissue support and facilitates positioning of the implanted tissue expander. The stage I implanted expander is a temporary implant. The stage II breast implant is intended to be a permanent implant, typically remaining implanted in the patient for ten or more years. The device also provides stabilization of the pectoralis muscle and can as well assist with maintenance of the position and appearance of the inframammary fold during stage I of a breast reconstruction and can provide this function after stage I as well. At the time of stage II (when the tissue expander is removed and the breast implant is implanted) the device is then fully or at least partially integrated within the underlying soft tissue which has grown into and around the pores of the scaffold. The device begins to be bioresorbed as soon as the device had been implanted in a patient and the device is completely bioresorbed after about one to four years after implantation. The device is implanted at stage I to help hold the tissue expander in place (the device is sutured in to form a pocket in which the tissue expander rests and/or the device is draped over the tissue expander). At the time of stage II when the tissue expander is removed and replaced by a breast implant (saline or gel filled) the device is not removed and the device remains in place within the patient.
  • Preferably, no additional or further device is implanted in the patient at stage II or thereafter. Importantly, the device implanted in the patient in stage I provides soft tissue support and along with the implanted tissue expander maintains the existence of a pocket or space during stage I (the tissue expansion stage) that is until the stage II breast implant implantation in the patient into the pocket or space so maintained during stage I. Thus the device assists to ensure that a pocket or space is available for the placement of the stage II breast implant. Significantly, the stage I implanted device is left in place implanted in the patient and is not removed. By stage II the device has be incorporated into the underlying soft tissue and vasculature has grown in and around it.
  • Preferably the scaffold is comprised entirely of or consists essentially of sericin depleted, knitted silkworm silk. The implanted device begins to be biodegraded or bioresorbed as soon as it is implanted in a patient. The fabric is completely (100%) bioresorbed (biodegraded) within about one year to about four years after implantation in a patient.
  • EXAMPLE 3 Use of Pliable Silk Device in Single Stage Breast Reconstruction
  • The device of Example 1 is supplied sterile in a single-use size with one device utilized per breast. The device is implanted in the subject immediately post mastectomy, during the breast implant placement surgery, in a direct-to-implant breast reconstruction procedure. In this Example the device is used in in DTI breast reconstruction is used.
  • Following mastectomy, the surgical site is readied for subpectoral breast implant insertion in accordance with standard surgical methods. The breast implant is rinsed in antibiotic solution and inserted into the subpectoral pocket. The device is optionally cut to size (prior to, during, and/or after suturing) to repair the void between the pectoral muscle and the chest wall (i.e., inframammary fold region). The device is rinsed with antibiotic solution and sutured in place to both the pectoralis muscle and chest wall, with a minimum suture bite of 3 mm or one full row of material. If any cutting was performed in situ, rinsing of the implant site is performed. Drains are placed according to usual standard of care and number and location of drain(s) noted. Rinsing of the surgical site with antibiotic solution and closure is performed. The surgical drain(s) is removed when deemed appropriate. The result is that the patient has breasts properly positioned and proportioned which look and feel like normal breasts. The same or a very similar procedure can be used for breast augmentation using the device.
  • EXAMPLE 4 General Surgical Procedures for use of the Device
  • The device can be used as a transitory scaffold for soft tissue support and repair to reinforce deficiencies where weakness or voids exist that require the addition of material to obtain the desired surgical outcome, including but not limited to reinforcement of soft tissues in reconstructive and plastic surgery to obtain the desired aesthetic outcome. The device should not be used in patients with a known allergy to silk nor in direct contact with bowel or viscera where formation of adhesions may occur. To use the device:
    • 1. irrigate and aspirate the device implant site with saline following the in situ cutting of the device to remove any device particulate debris that may have been generated.
    • 2. the device is stored in its original sealed package away from direct sources of heat at ambient room temperature.
    • 3. handle the device using aseptic technique and sterile talc-free gloves.
    • 4. remove the device from the package. Although the device does not require rehydration for mechanical or physical performance, a brief incubation (minimum 2-3 seconds) in sterile rinse solution is recommended prior to implantation.
    • 5. use the type of suture or fixation system that is appropriate for the patient use.
    • 6. sutures should be placed at least 3 mm, or one full row, from the cut edge of the device .
    • 7. If preferred, the uncut device can be sutured over the patient defect and trimmed once secured in place followed by rinsing and aspiration.
    • 8. the device should be sufficiently anchored to stabilize it during tissue ingrowth.
    • 9. for laparoscopic procedures the device should be rolled along its long axis and may be delivered through a ⅞ mm or larger cannula.
    EXAMPLE 5 Use of the Pliable Silk Device for Hernia Repair
  • In general, there are two main types of hernia repair: open hernia repair and minimally invasive (laparoscopic) repair. Open repair is a traditional hernia repair procedure. There are numerous and varied approaches for performing this type of hernia repair. Such approaches are performed routinely with local and intravenous sedation. Due to the larger size of the incision, open hernia repair is generally painful with a relatively long recovery period. Minimally invasive (laparoscopic) repair is usually performed under general anesthesia. Spinal anesthesia and local anesthesia are used under certain circumstances. Benefits associated with minimally invasive (laparoscopic) repair include shorter operative time, less pain, and a shorter recovery period.
  • In laparoscopic hernia surgery, a telescope attached to a camera is inserted through a small incision that is made under the patient's belly button. Two other small cuts are made in the lower abdomen. The hernia defect is reinforced with a mesh and secured in position. The device is secured in position by stitches, staples, tacks, and glue.
  • Another form of laparoscopic hernia repair is ventral hernia repair (laparoscopic). Incisional, ventral, epigastric, or umbilical hernias are defects of the anterior abdominal wall and may be congenital (umbilical hernia) or acquired (incisional). Incisional hernias form after surgery through the incision site or previous drain sites, or laparoscopic trocar insertion sites. Incisional hernias often occur after open surgical procedures. These hernias present with a bulge near or at a previous incision. The device (a prosthetic mesh) is used in order to minimize tension on the repair so as to reduce the chance of hernia recurrence. Traditionally, an old incision scar is incised and removed. Inspection of the entire length of the incision generally uncovers multiple hernia defects. The area requiring coverage is usually large and requires much surgical dissection. The device is used to cover the defect before closure of the wound. This is a major and often complex surgical procedure. The use of the device decreases possible recurrence. A patient typically returns to normal activity within a matter of weeks. The principles governing a laparoscopic ventral hernia repair are based on those of open Stoppa ventral hernia repair. A large piece of the device is placed under the hernia defect with a wide margin of mesh outside the defect, and the mesh is anchored in to place and secured to the anterior abdominal wall. The device is anchored into place, for example, by sutures. The device is secured to the anterior abdominal wall, for example, by tacks which are placed laparoscopically.
  • EXAMPLE 6 Use of the Pliable Silk Device in Abdominoplasty
  • The device can be used in body aesthetics and body contouring surgical procedures. One such embodiment relates to use of the device in abdominoplasty. There are various surgical procedures for performing an abdominoplasty depending upon the type of abdominoplasty to be performed. The time needed for conducting an abdominoplasty also varies depending upon the type of abdominoplasty to be performed. For example, a complete abdominoplasty typically is completed in 1 to 5 hours. A partial abdominoplasty, also referred to as a mini-tuck abdominoplasty, is typically completed in 1 to 2 hours. Following an abdominoplasty surgical procedure, reconstruction of the umbilicus, commonly referred to as the belly button, may also occur. The original umbilicus is attached, such as by sutures, into a new hole created by the surgeon.
  • A complete abdominoplasty is also referred to as a full abdominoplasty. In a complete abdominoplasty, an incision is made from hip to hip just above the pubic area. Another incision is made to separate the navel from the surrounding skin. The skin is detached from the abdominal wall to reveal the muscles and fascia to be tightened. The muscle fascia wall is tightened with sutures. The remaining skin and fat are tightened by removing the excess and closing. The old belly button stalk is brought out through a new hole and sutured into place. Liposuction may also be used to refine the transition zones of the abdominal contouring. A surgical dressing and optionally a compression garment are applied. Excess fluid from the site is drained. A complete abdominoplasty may also comprise a musculofascial plication abdominal dermal lipectomy and/or suction-assisted lipectomy of hips.
  • A partial abdominoplasty is also referred to as a mini abdominoplasty. In a partial abdominoplasty, a smaller incision is made as compared to a complete abdominoplasty. The skin and fat of the lower abdomen are detached in a more limited manner from the muscle fascia. The skin is stretched down and excess skin removed. The belly button stalk may be divided from the muscle below and the belly button slid down lower on the abdominal wall.
  • A portion of the abdominal muscle fascia wall is optionally tightened. Liposuction is often used to contour or sculpt the transition zone. The flap is stitched back into place. A combination abdominoplasty and liposuction procedure is often referred to as a “lipo-tuck”. During such procedure, skin is removed and subsequently sutured. As noted above, the belly button is reattached to a new hole created by the surgeon.
  • An extended abdominoplasty is a complete abdominoplasty plus a lateral thigh lift. The patient is cut from the posterior axillary line. The operation includes all of the abdominal contouring of a complete abdominoplasty plus allows further improvement of the flank (waist), as well as smoothing the contour of the upper lateral thigh.
  • A high lateral tension tummy tuck is a more involved procedure and typically takes at least four and half hours to perform. In this method, in addition to vertical-line tightening as is the case in most conventional abdominoplasty procedures, muscles are also tightened horizontally. The procedure provides a patient with a flat abdomen and with an improved waistline.
  • A circumferential abdominoplasty, also referred to as a belt lipectomy or body lift, is an extended abdominoplasty in conjunction with a buttock lift. The incision typically runs all the way around the body. This surgical procedure is suitable, for example, for patients who have undergone massive weight loss.
  • The above procedures can be used alone or in combination. For example, an abdominoplasty may be conducted in the course of a lower body lift. Alternatively, abdominoplasty is combinable with liposuction contouring, breast reduction, breast lift, or a hysterectomy. Breast enhancement procedures performed in conjunction with an abdominoplasty are often referred to as a “mommy makeover”. In such a procedure, barbed sutures may be employed.
  • An abdominoplasty procedure can be conducted using the device The typical fascial is done first, using a row of figure of eight sutures, first and then another layer of running suture all #1 PDS (polydioxanone suture, Ethicon) Two pieces of the device can be used as an onlay to augment the fascia tightening. One 10×25 cm piece can be used in the lower abdomen. It can be laced transversely, the vertical dimension 10 cm, can be positioned with the lower edge at level of the pubic symphsis, and the upper edge at the lower border of the umbilicus. The 25 cm transverse dimension can be suitable. A second scaffold can be cut and tailored to use in the supra-umbilcal region, with care taken not to leave too close to the umbilical closure. As the closure around the umbilicus occasionally may not heal primarily, extra care is taken with sutures/device in this location.
  • The handling characteristics can be excellent. The device is secured at its periphery with a 3-0 V-Lock (COVIDIEN brand of barbed suture, made of a material similar to PDS).
  • The patient can do very well and can be hospitalized overnight. The patient has a total of 5, ten mm flat blake drains—two that drain the back and three in the front. The patient stays on antibiotics until drains were which is typically within 10 to 20 days.
  • To summarize a device according to the present invention is a biocompatible, bioresorbable, pliable surgical matrix (mesh or scaffold) made preferably from the silk of the Bombyx mori silkworm. Because raw silk fibers are comprised of a fibroin protein core filament that is naturally coated with the antigenic globular protein sericin the sericin is removed by aqueous extraction. Yarn is then made from the sericin-depleted fibroin protein filaments by helical twisting to form a multi-filament protein fiber. The multi-filament protein fiber yarn is then knit into a three dimensional patterned matrix (mesh or scaffold) that can be used for soft tissue support and repair. The device upon implantation provides immediate physical and mechanical stabilization of tissue defects because of its strength and porous construction. Additionally, the porous lattice design of the device facilitate native tissue generation (that is tissue ingrowth) and neovascularization. The natural tissue repair process begins with deposition of a collagen network. This network integrates within the protein matrix, interweaving with the porous construct. Neovascularization begins with endothelial cell migration and blood vessel formation in the developing functional tissue network. This new functional tissue network and its corresponding vascular bed ensure the structural integrity and strength of the tissue. In the beginning stages of the tissue ingrowth process, the device provides the majority of structural support. The device (made of silk) is gradually deconstructed (bioresorbed) into its amino acid building blocks. The slow progression of the natural biological process of bioresorption allows for the gradual transition of support from the protein matrix of the device to the healthy native tissue thereby achieving the desired surgical outcome.

Claims (12)

What is claimed is:
1. A process for making a pliable, knitted surgical mesh, the process comprising the steps of:
knitting a first silk yarn in a first wale direction;
knitting a second silk yarn in a second wale direction;
knitting a third silk yarn in a first course direction; and
knitting a fourth silk yarn in a second course direction;
thereby obtaining the pliable knitted surgical mesh.
2. The process of claim 1 wherein one of the first or the second silk yarns are knitted using the knit pattern 3/1-1/1-1/3-3/3.
3. The process of claim 2 wherein the other of the first or the second silk yarns are knitted using the knit pattern 1/1-1/3-3/3-3/1.
4. The process of claim 1, wherein the two movements in the wale direction occur on separate needle beds using a knitting machine having two needle beds.
5. The process of claim 2, wherein the two movements in the wale direction occur on separate needle beds using a knitting machine having two needle beds.
6. The process of claim 3, wherein the two movements in the wale direction occur on separate needle beds using a knitting machine having two needle beds.
7. The process of claim 1 wherein the silk yarns are made of a nine filaments twisted, and sericin depleted silk fibers.
8. A surgical mesh made using the process of claim 1.
9. A surgical mesh made using the process of claim 2.
10. A surgical mesh made using the process of claim 3.
11. A surgical mesh made using the process of claim 4.
12. A surgical mesh made using the process of claim 7.
US15/066,876 2008-12-15 2016-03-10 Pliable silk medical device Abandoned US20160193026A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/066,876 US20160193026A1 (en) 2008-12-15 2016-03-10 Pliable silk medical device

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US12252008P 2008-12-15 2008-12-15
PCT/US2009/063717 WO2010074827A2 (en) 2008-12-15 2009-11-09 A prosthetic device and method of manufacturing the same
US13/156,283 US20120004723A1 (en) 2008-12-15 2011-06-08 Prosthetic device and method of using in breast augmentation and/or breast reconstruction
US13/186,151 US20120022646A1 (en) 2008-12-15 2011-07-19 Prosthetic device and method of using in breast augmentation and/or breast reconstruction
US68040411A 2011-09-19 2011-09-19
US13/306,325 US20120185041A1 (en) 2008-12-15 2011-11-29 Silk medical device for use in breast augmentation and breast reconstruction
US13/715,872 US20130317526A1 (en) 2008-12-15 2012-12-14 Silk medical device
US14/462,473 US9308070B2 (en) 2008-12-15 2014-08-18 Pliable silk medical device
US15/066,876 US20160193026A1 (en) 2008-12-15 2016-03-10 Pliable silk medical device

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US14/462,473 Continuation US9308070B2 (en) 2008-12-15 2014-08-18 Pliable silk medical device

Publications (1)

Publication Number Publication Date
US20160193026A1 true US20160193026A1 (en) 2016-07-07

Family

ID=53183260

Family Applications (2)

Application Number Title Priority Date Filing Date
US14/462,473 Expired - Fee Related US9308070B2 (en) 2008-12-15 2014-08-18 Pliable silk medical device
US15/066,876 Abandoned US20160193026A1 (en) 2008-12-15 2016-03-10 Pliable silk medical device

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US14/462,473 Expired - Fee Related US9308070B2 (en) 2008-12-15 2014-08-18 Pliable silk medical device

Country Status (1)

Country Link
US (2) US9308070B2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10660741B2 (en) * 2015-04-24 2020-05-26 Sofradim Production Prosthesis for supporting a breast structure
US20220296357A1 (en) * 2019-06-21 2022-09-22 Lazzaro Medical, LLC Airway support device
US12064330B2 (en) 2020-04-28 2024-08-20 Covidien Lp Implantable prothesis for minimally invasive hernia repair

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9326840B2 (en) 2008-12-15 2016-05-03 Allergan, Inc. Prosthetic device and method of manufacturing the same
US20130317526A1 (en) * 2008-12-15 2013-11-28 Allergan, Inc. Silk medical device
US9308070B2 (en) * 2008-12-15 2016-04-12 Allergan, Inc. Pliable silk medical device
JP2012171124A (en) * 2011-02-18 2012-09-10 Sekisui Chem Co Ltd Pipe making member and method of regenerating existing pipe
US20150057685A1 (en) * 2013-08-22 2015-02-26 Allergan, Inc. Medical device with anti adhesive property
AU2015320722A1 (en) * 2014-09-23 2017-04-13 Cytex Therapeutics, Inc. Articular cartilage repair
EP3029189B1 (en) 2014-12-05 2021-08-11 Sofradim Production Prosthetic porous knit, method of making same and hernia prosthesis
US10603154B2 (en) * 2015-03-31 2020-03-31 Prevent Patch, LLC Devices and methods for preventing incisional hernias
CA3005604C (en) * 2015-11-19 2023-07-18 Tepha, Inc. Methods to produce perforated collagen coated surgical meshes
WO2017132405A1 (en) * 2016-01-26 2017-08-03 Sofregen Medical Ireland Limited Pliable silk medical device
WO2017192227A1 (en) * 2016-05-04 2017-11-09 Trustees Of Tufts College Silk nanofibrils and uses thereof
US10945831B2 (en) 2016-06-03 2021-03-16 Musculoskeletal Transplant Foundation Asymmetric tissue graft
USD856517S1 (en) 2016-06-03 2019-08-13 Musculoskeletal Transplant Foundation Asymmetric tissue graft
US10385483B2 (en) * 2017-09-25 2019-08-20 Ping-Kun Lin Woven textile
USD897116S1 (en) * 2018-01-10 2020-09-29 Yupoong, Inc. Cloth for a cap
US11730156B2 (en) * 2018-04-06 2023-08-22 Loren James Wilcox Renewable natural fiber fishing line
DE102018113810A1 (en) * 2018-06-11 2019-12-12 Cortronik GmbH Function marker element and method for its production
US10813743B2 (en) 2018-09-07 2020-10-27 Musculoskeletal Transplant Foundation Soft tissue repair grafts and processes for preparing and using same
USD895812S1 (en) 2018-09-07 2020-09-08 Musculoskeletal Transplant Foundation Soft tissue repair graft
US11058532B2 (en) 2019-02-07 2021-07-13 Biorez, Inc. Composite scaffold for the repair, reconstruction, and regeneration of soft tissues
US11535729B2 (en) 2021-02-08 2022-12-27 Enviro Cast, LLC Degradable fishing lines and nets
EP4104799A1 (en) * 2021-06-16 2022-12-21 Discoseal BV Patch for covering a defect in the annulus fibrosus of an intervertebral disc, and in particular also in the posterior longitudinal ligament, of a spine
CN114870081B (en) * 2022-07-12 2022-11-01 北京大学人民医院 Warp-knitted silk fibroin patch for the treatment of female pelvic floor dysfunction

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3448595A (en) * 1965-10-15 1969-06-10 Ludwig Povel & Co Kg Warp knitted fabric suitable for bandaging and the like
US4391106A (en) * 1978-02-22 1983-07-05 Karl Otto Braun K.G. Wound dressing
US4476697A (en) * 1980-04-21 1984-10-16 Karl Otto Braun Kg Wound dressing
US20030149464A1 (en) * 2001-07-03 2003-08-07 Scimed Life Systems, Inc. Low profile, high stretch knit prosthetic device
US20050070829A1 (en) * 2003-09-16 2005-03-31 Sofradim Production Prosthetic knit with variable properties
US9445883B2 (en) * 2011-12-29 2016-09-20 Sofradim Production Barbed prosthetic knit and hernia repair mesh made therefrom as well as process for making said prosthetic knit
US9499927B2 (en) * 2012-09-25 2016-11-22 Sofradim Production Method for producing a prosthesis for reinforcing the abdominal wall
US9554887B2 (en) * 2011-03-16 2017-01-31 Sofradim Production Prosthesis comprising a three-dimensional and openworked knit

Family Cites Families (291)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3124136A (en) * 1964-03-10 Method of repairing body tissue
US848605A (en) * 1905-07-15 1907-03-26 Peter Schmid Process for ungumming silk.
US955541A (en) 1908-05-08 1910-04-19 Petersen Circular Loom Company Woven tubular fabric.
US1300696A (en) 1918-03-11 1919-04-15 Sibson & Stern Inc Reinforcing fabric strip for tires
US1709662A (en) * 1925-10-30 1929-04-16 Celanese Corp Process of degumming
US1815279A (en) * 1927-11-29 1931-07-21 Takamine Ferment Company Process of degumming silk
DE534571C (en) * 1928-11-14 1931-09-28 I G Farbenindustrie Akt Ges Process for spinning solutions of silk fibroin in phosphoric acid by means of falling balls
BE367138A (en) * 1930-02-03
US1828736A (en) * 1930-02-03 1931-10-27 Carbide & Carbon Chem Corp Degumming silk
US1921022A (en) * 1931-07-25 1933-08-08 Bell Telephone Labor Inc Submarine cable signaling system
US1927022A (en) 1931-12-17 1933-09-19 Humberto L Bueno Art of treating natural and artificial silk and agents therefor
GB415027A (en) * 1933-01-11 1934-08-13 British Celanese Improvements in or relating to the degumming of silk
NL301512A (en) 1962-12-08
US3672187A (en) 1967-05-19 1972-06-27 Polylok Corp Fabric
US3595276A (en) * 1969-01-21 1971-07-27 Rolls Royce Method and apparatus for introducing a weft thread into a sheet of warp threads
US3552154A (en) 1969-04-14 1971-01-05 Deering Milliken Res Corp Knit fabric
US3931721A (en) * 1974-07-22 1976-01-13 Vf Corporation Warp knitted elastic fabric
US3952555A (en) 1974-08-13 1976-04-27 Deering Milliken Research Corporation Warp knit denim fabrics
US3922888A (en) 1974-09-11 1975-12-02 Deering Milliken Res Corp Warp knit twill, sharkskin and pique fabrics
US3999407A (en) 1975-04-01 1976-12-28 Stedman Corporation Embossed striped elastic warp knit fabric and method of making same
US4340091A (en) * 1975-05-07 1982-07-20 Albany International Corp. Elastomeric sheet materials for heart valve and other prosthetic implants
US4089071A (en) * 1976-09-08 1978-05-16 Kalnberz Viktor Konstantinovic Material for making bone endoprosthesis and endoprosthesis made of said material
US4118842A (en) * 1977-07-08 1978-10-10 Champion International Corporation Weave-de-weave process
US4141207A (en) * 1977-09-02 1979-02-27 Shigesaburo Mizushima Process for producing curl shrunk silk yarn
US4248064A (en) 1979-02-14 1981-02-03 Stedman Corporation Lock-stitch knitted elastic fabric
US4282954A (en) 1980-02-11 1981-08-11 Hill John O Rewinder device
US4347847A (en) 1980-06-06 1982-09-07 Usher Francis C Method of hernia repair
US4388364A (en) 1982-06-04 1983-06-14 Milliken Research Corportion Heat set warp knit weft inserted fabric and coating thereof
US4461298A (en) 1982-07-26 1984-07-24 Ethicon, Inc. Composite sutures of silk and hydrophobic thermoplastic elastomers
DE3304345C2 (en) 1983-02-09 1986-04-10 Karl Mayer Textil-Maschinen-Fabrik Gmbh, 6053 Obertshausen Warp knitted fabric with reinforcement threads
US4530113A (en) 1983-05-20 1985-07-23 Intervascular, Inc. Vascular grafts with cross-weave patterns
US4631188A (en) 1983-08-31 1986-12-23 S.K.Y. Polymers, Ltd. (Kingston Technologies) Injectable physiologically-acceptable polymeric composition
US4605691A (en) 1984-12-06 1986-08-12 Biomatrix, Inc. Cross-linked gels of hyaluronic acid and products containing such gels
US4865031A (en) 1985-07-12 1989-09-12 Keeffe Paul J O Fabric and method of use for treatment of scars
US4987665A (en) * 1986-03-03 1991-01-29 American Cyanamid Company Prosthetic tubular article
US4792336A (en) * 1986-03-03 1988-12-20 American Cyanamid Company Flat braided ligament or tendon implant device having texturized yarns
DE3661880D1 (en) * 1986-04-22 1989-03-02 Braun Karl Otto Kg Layered textile wound dressing
GB8630363D0 (en) 1986-12-19 1987-01-28 Igel Int Ltd Coloured hydrogel objects
US5250077A (en) * 1987-04-28 1993-10-05 Kanebo Co., Ltd. Silk fiber having good abrasion resistance and good light resistance and methods for the preparation thereof
US4816028A (en) * 1987-07-01 1989-03-28 Indu Kapadia Woven vascular graft
US5261886A (en) * 1987-08-26 1993-11-16 United States Surgical Corporation Cabled core and braided suture made therefrom
US5606019A (en) * 1987-10-29 1997-02-25 Protien Polymer Technologies, Inc. Synthetic protein as implantables
US5120829A (en) 1989-03-20 1992-06-09 La Jolla Cancer Research Foundation Hydrophobic attachment site for adhesion peptides
US5191777A (en) 1989-03-27 1993-03-09 Burlington Industries, Inc. Weft inserted, warp knit, woven-look fabric and apparatus and methods of making the fabric
DE3917174C2 (en) 1989-05-26 1993-11-04 Heimbach Gmbh Thomas Josef GAS FILTER AGENT
US5245012A (en) 1990-04-19 1993-09-14 The United States Of America As Represented By The Secretary Of The Army Method to achieve solubilization of spider silk proteins
US5989894A (en) 1990-04-20 1999-11-23 University Of Wyoming Isolated DNA coding for spider silk protein, a replicable vector and a transformed cell containing the DNA
US5178630A (en) * 1990-08-28 1993-01-12 Meadox Medicals, Inc. Ravel-resistant, self-supporting woven graft
SE9102448D0 (en) * 1990-08-28 1991-08-26 Meadox Medicals Inc RAVEL RESISTANT, SELF-SUPPORTING WOVEN GRAFT
US5171505A (en) * 1990-11-28 1992-12-15 E. I. Du Pont De Nemours And Company Process for spinning polypeptide fibers
KR0185215B1 (en) 1990-11-30 1999-05-01 요시다 쇼오지 Sustained release eye drops
EP0513803A2 (en) * 1991-05-17 1992-11-19 Japan Vilene Company, Ltd. Carrier for immobilization of animal cells, process for manufacture thereof, and methods for cultivation
SE9101853D0 (en) 1991-06-17 1991-06-17 Jonas Wadstroem IMPROVED TISSUE ASHESIVE
US5366504A (en) * 1992-05-20 1994-11-22 Boston Scientific Corporation Tubular medical prosthesis
US5134006A (en) * 1991-12-05 1992-07-28 The Goodyear Tire & Rubber Company Belt reinforcing fabric and a belt reinforced with the same
US5252285A (en) * 1992-01-27 1993-10-12 E. I. Du Pont De Nemours And Company Process for making silk fibroin fibers
US5456711A (en) * 1992-05-15 1995-10-10 Intervascular Inc. Warp knitted carotid patch having finished selvedged edges
GB9212697D0 (en) 1992-06-15 1992-07-29 Short Brothers Plc Composite structure manufacture
US5353486A (en) * 1992-11-13 1994-10-11 Minnesota Mining And Manufacturing Company Narrow fiberglass knit tape
US6159877A (en) * 1993-01-25 2000-12-12 3M Innovative Properties Company Fabric backing for orthopedic support materials
JPH08506060A (en) 1993-02-04 1996-07-02 フアウペル テクステイルマシーネン コマンデイトゲゼルシヤフト Device for ultrasonically cutting and / or ultrasonically welding webs
JPH06245989A (en) 1993-02-24 1994-09-06 Nippon Shoji Kk Suture yarn for operation and its production
CA2149900C (en) 1993-09-24 2003-06-24 Yasuo Shikinami Implant material
JPH07298876A (en) 1994-03-09 1995-11-14 Res Dev Corp Of Japan Liquid-permeable cell culture carrier, culture method and culture apparatus using this carrier
WO1995025550A1 (en) 1994-03-22 1995-09-28 Organogenesis Inc. Biocompatible prosthetic devices
US6113623A (en) * 1994-04-20 2000-09-05 Cabinet Beau De Lomenie Prosthetic device and method for eventration repair
FR2720266B1 (en) * 1994-05-27 1996-12-20 Cogent Sarl Prosthetic fabric.
US6074722A (en) 1994-09-30 2000-06-13 Lockheed Martin Corporation Flexible material for use in an inflatable structure
US5716404A (en) 1994-12-16 1998-02-10 Massachusetts Institute Of Technology Breast tissue engineering
US5700559A (en) 1994-12-16 1997-12-23 Advanced Surface Technology Durable hydrophilic surface coatings
US5741332A (en) 1995-01-23 1998-04-21 Meadox Medicals, Inc. Three-dimensional braided soft tissue prosthesis
JPH08295697A (en) 1995-04-26 1996-11-12 Kanebo Ltd Production of aqueous solution of silk fibroin at high concentration
GB9510624D0 (en) * 1995-05-25 1995-07-19 Ellis Dev Ltd Textile surgical implants
US5643043A (en) 1995-05-31 1997-07-01 Pflum; Trish Winsche Brassiere for female athletes
US6129761A (en) 1995-06-07 2000-10-10 Reprogenesis, Inc. Injectable hydrogel compositions
JPH0931798A (en) * 1995-07-07 1997-02-04 Toru Takada Silk velvet fabric or knitted fabric and its production
US5569273A (en) * 1995-07-13 1996-10-29 C. R. Bard, Inc. Surgical mesh fabric
US5584884A (en) 1995-07-27 1996-12-17 Anthony S. Pignataro Mammary prosthesis and method of surgically implanting same
IL123398A0 (en) 1995-08-22 1998-09-24 Agricola Tech Inc Cloning methods for high strength spider silk proteins
US5795835A (en) 1995-08-28 1998-08-18 The Tensar Corporation Bonded composite knitted structural textiles
US5771716A (en) * 1995-09-18 1998-06-30 Schlussel; Edward Warp-knitted loop net fabric
US5965125A (en) 1995-10-25 1999-10-12 Transkaryotic Therapies, Inc. Hybrid matrix implants and explants
JP2997758B2 (en) * 1996-01-23 2000-01-11 農林水産省蚕糸・昆虫農業技術研究所長 Wound dressing
JP3023431B2 (en) 1996-02-23 2000-03-21 株式会社山嘉精練 Method for producing woven / knitted fabric using yarn-dyed silk yarn and woven / knitted fabric produced thereby
AU2334897A (en) 1996-03-18 1997-10-10 Regents Of The University Of California, The Peptide inhibitors of neurotransmitter secretion by neuronal cells
US6592617B2 (en) * 1996-04-30 2003-07-15 Boston Scientific Scimed, Inc. Three-dimensional braided covered stent
US5800514A (en) * 1996-05-24 1998-09-01 Meadox Medicals, Inc. Shaped woven tubular soft-tissue prostheses and methods of manufacturing
US6004888A (en) 1996-07-16 1999-12-21 Teijin Limited Fibrous sheet for structure reinforcement and structure reinforced with same
JP2001505539A (en) 1996-08-07 2001-04-24 プロテイン・スペシャルティーズ,リミテッド Self-aligned peptides from elastin and other filamentous proteins
US7049346B1 (en) 1996-08-20 2006-05-23 Menlo Care Div Of Ethicon, Inc. Swollen hydrogel for sphincter augmentation
FR2755846B1 (en) * 1996-11-20 1998-12-31 Jacques Philippe Laboureau PRE-ORIENT PROSTHETIC LIGAMENT AND METHOD OF MAKING
CA2274661A1 (en) 1996-12-10 1998-06-18 Reprogenesis, Inc. Improved hydrogel for tissue engineering
US6146418A (en) * 1997-02-28 2000-11-14 Berman; Mark Body implant and method of implanting
US6120539A (en) 1997-05-01 2000-09-19 C. R. Bard Inc. Prosthetic repair fabric
US6218480B1 (en) 1997-06-16 2001-04-17 Mmr Technologies, Inc. Water-compatible urethane-containing amine hardener
US6175053B1 (en) 1997-06-18 2001-01-16 Japan As Represented By Director General Of National Institute Of Sericultural And Entomological Science Ministry Of Agriculture, Forrestry And Fisheries Wound dressing material containing silk fibroin and sericin as main component and method for preparing same
FR2766698B1 (en) * 1997-08-01 1999-11-05 Cogent Sarl ADJUSTED THREE-DIMENSIONAL PROSTHETIC FABRIC
US6042592A (en) * 1997-08-04 2000-03-28 Meadox Medicals, Inc. Thin soft tissue support mesh
US6090116A (en) * 1997-10-03 2000-07-18 D'aversa; Margaret M. Knitted surgical mesh
WO1999025811A1 (en) * 1997-11-18 1999-05-27 Japan As Represented By Director General Of National Institute Of Sericultural And Entomological Science Ministry Of Agriculture, Forestry And Fisheries Epidermal cell growth activating material
US6171984B1 (en) 1997-12-03 2001-01-09 Ppg Industries Ohio, Inc. Fiber glass based geosynthetic material
JP3587673B2 (en) 1997-12-26 2004-11-10 Ykk株式会社 Braided slide fastener
US5994099A (en) 1997-12-31 1999-11-30 The University Of Wyoming Extremely elastic spider silk protein and DNA coding therefor
US6076448A (en) 1998-01-22 2000-06-20 Rexroad; John Method of using barrier material and system
FR2774703B1 (en) 1998-02-11 2000-04-21 Picardie Lainiere DRAPERY FABRIC, MANUFACTURING METHOD THEREOF AND USES THEREOF
US6233978B1 (en) 1998-04-09 2001-05-22 Gehring Textiles, Inc. Pointed thrust weapons protective fabric system
US6303136B1 (en) * 1998-04-13 2001-10-16 Neurotech S.A. Cells or tissue attached to a non-degradable filamentous matrix encapsulated by a semi-permeable membrane
US6110590A (en) * 1998-04-15 2000-08-29 The University Of Akron Synthetically spun silk nanofibers and a process for making the same
FR2779937B1 (en) * 1998-06-23 2000-08-11 Sofradim Production ADJUSTED ISOELASTIC PROSTHETIC FABRIC
US6159239A (en) * 1998-08-14 2000-12-12 Prodesco, Inc. Woven stent/graft structure
US6530956B1 (en) 1998-09-10 2003-03-11 Kevin A. Mansmann Resorbable scaffolds to promote cartilage regeneration
US7662409B2 (en) 1998-09-25 2010-02-16 Gel-Del Technologies, Inc. Protein matrix materials, devices and methods of making and using thereof
US6630414B1 (en) * 1998-10-14 2003-10-07 Asahi Doken Kabushiki Kaisha Three-dimensional net, and composite structural material using the same
WO2000033771A2 (en) 1998-12-11 2000-06-15 Johnson Gerald W Implants filled with solid or semi-solid material
US6287316B1 (en) 1999-03-26 2001-09-11 Ethicon, Inc. Knitted surgical mesh
US6175533B1 (en) * 1999-04-12 2001-01-16 Lucent Technologies Inc. Multi-port memory cell with preset
NO311317B1 (en) 1999-04-30 2001-11-12 Thin Film Electronics Asa Apparatus comprising electronic and / or optoelectronic circuits and method of realizing and / or integrating circuits of this kind in the apparatus
US6258124B1 (en) 1999-05-10 2001-07-10 C. R. Bard, Inc. Prosthetic repair fabric
US6287340B1 (en) 1999-05-14 2001-09-11 Trustees Of Tufts College Bioengineered anterior cruciate ligament
GB9912240D0 (en) 1999-05-27 1999-07-28 Smith & Nephew Implantable medical devices
JP3362778B2 (en) 1999-06-03 2003-01-07 独立行政法人農業生物資源研究所 Method for producing ultrafine crystalline silk powder
ATE334639T1 (en) * 1999-06-08 2006-08-15 Ethicon Inc SURGICAL KNITTED FABRIC
DE19928635C1 (en) 1999-06-23 2000-10-05 Saechsisches Textilforsch Inst Multi-axial warp knitted fabric has at least two diagonal yarn systems with standing wefts and structured part-wefts on variable alignments to give force lines in all directions
US6506394B1 (en) 1999-06-30 2003-01-14 Kimberly-Clark Worldwide, Inc. Delivery of a botanical extract to a treated substrate for transfer to skin
DE19942611C1 (en) * 1999-08-31 2001-07-05 Ethicon Gmbh Reinforced flat implant
DE19954166A1 (en) * 1999-11-10 2001-05-17 Inst Textil & Faserforschung Flat implant, method for its production and use in surgery
JP2001163899A (en) * 1999-12-09 2001-06-19 Natl Inst Of Sericultural & Entomological Science Production method of functional silk fibroin and its use
WO2002050352A1 (en) * 2000-12-18 2002-06-27 Asahi Doken Kabushiki Kaisha Double knitted fabric
US6228132B1 (en) * 1999-12-17 2001-05-08 Innovative Products Process for modifying silk
US6620917B1 (en) 2000-01-20 2003-09-16 The United States Of America As Represented By The Secretary Of The Army Method for the purification and aqueous fiber spinning of spider silks and other structural proteins
JP2003533468A (en) 2000-02-28 2003-11-11 ゲル−デル テクノロジーズ,インコーポレイティド Protein matrix materials, production and their production and use
DE10019604C2 (en) * 2000-04-20 2002-06-27 Ethicon Gmbh implant
FR2807937B1 (en) * 2000-04-20 2002-08-02 Sofradim Production GRIPPED PROSTHETIC KNIT, MANUFACTURING METHOD THEREOF AND REINFORCEMENT IMPLANT FOR THE TREATMENT OF WALL DEFICITS
US6729356B1 (en) * 2000-04-27 2004-05-04 Endovascular Technologies, Inc. Endovascular graft for providing a seal with vasculature
US6730016B1 (en) 2000-06-12 2004-05-04 Acorn Cardiovascular, Inc. Cardiac disease treatment and device
AU6888201A (en) 2000-06-29 2002-01-08 Biosyntech Canada Inc Composition and method for the repair and regeneration of cartilage and other tissues
US20020025340A1 (en) 2000-08-30 2002-02-28 Dyer Wallace K. Methods and compositions for tissue augmentation
US7025063B2 (en) * 2000-09-07 2006-04-11 Ams Research Corporation Coated sling material
US7404819B1 (en) 2000-09-14 2008-07-29 C.R. Bard, Inc. Implantable prosthesis
DE10046119A1 (en) * 2000-09-15 2002-03-28 Inst Textil & Faserforschung Medical bioresorbable implant, method of manufacture and use
IT1316885B1 (en) * 2000-10-02 2003-05-13 Consorzio Per Gli Studi Uni PROCEDURE FOR THE PREPARATION OF A NON-WOVEN FABRIC IN SILK FIBER.
GB0024903D0 (en) 2000-10-11 2000-11-22 Ellis Dev Ltd A textile prothesis
DE10050199A1 (en) * 2000-10-11 2002-04-25 Ethicon Gmbh Areal implant having a flexible basic structure on a polymer basis, contains ultrasonically detectable elements, which contain or produce gas and set up for detectability for at least four weeks after implantation
JP2002128691A (en) * 2000-10-24 2002-05-09 National Institute Of Agrobiological Sciences Sericin-containing material, its production method and its use
JP3490070B2 (en) * 2000-12-05 2004-01-26 健一 横山 Stretch fabric material for medical use
US20020156437A1 (en) * 2000-12-22 2002-10-24 Kimberly-Clark Worldwide, Inc. Removal of targeted proteases with proteinaceous wound dressings containing growth factors
US6783554B2 (en) * 2001-02-20 2004-08-31 Atrium Medical Corporation Pile mesh prosthesis
US6827743B2 (en) * 2001-02-28 2004-12-07 Sdgi Holdings, Inc. Woven orthopedic implants
US20030183978A1 (en) * 2001-03-14 2003-10-02 Tetsuo Asakura Method of producing fiber and film of silk and silk-like material
GB0108088D0 (en) * 2001-03-30 2001-05-23 Browning Healthcare Ltd Surgical implant
GB0108181D0 (en) * 2001-04-02 2001-05-23 Xiros Plc Silk-based fibre
US20040209538A1 (en) 2001-06-26 2004-10-21 Uwe Klinge Textile implant
JP2005502078A (en) 2001-08-31 2005-01-20 フェデラル−モーグル パワートレイン インコーポレイテッド Optical fiber support
ITVR20010098A1 (en) 2001-09-11 2003-03-11 Consorzio Per Gli Studi Uni PROCEDURE FOR OBTAINING SILK FIBROIN HYDROGELS.
AUPR806701A0 (en) 2001-10-03 2001-10-25 Gale Pacific Limited Knitted fabric
FR2830434B1 (en) * 2001-10-05 2004-01-02 Sofradim Production THREE-DIMENSIONAL TRICOT WALL REINFORCEMENT AND ADJUSTMENT
CN1277584C (en) 2001-10-25 2006-10-04 康涅狄格大学 Biologically active substances, methods of preparing biologically active substances and methods of use thereof
AUPR886301A0 (en) 2001-11-14 2001-12-06 Gale Pacific Limited Knitted mesh fabric
US20110009960A1 (en) * 2001-11-16 2011-01-13 Allergan, Inc. Prosthetic fabric structure
US6902932B2 (en) 2001-11-16 2005-06-07 Tissue Regeneration, Inc. Helically organized silk fibroin fiber bundles for matrices in tissue engineering
US7651684B2 (en) 2001-12-07 2010-01-26 Cytori Therapeutics, Inc. Methods of using adipose tissue-derived cells in augmenting autologous fat transfer
WO2003060207A1 (en) 2002-01-09 2003-07-24 E. I. Du Pont De Nemours And Company Polypeptide fibers and processes for making them
DK200200483A (en) 2002-04-02 2003-10-03 Tytex As Bra, especially useful for breastfeeding
DE10221320A1 (en) * 2002-05-07 2003-11-27 Gfe Medizintechnik Gmbh Flat implant made of textile thread material, especially hernia mesh
JP3973483B2 (en) * 2002-05-08 2007-09-12 Ykk株式会社 Elastic warp knitted fabric
US6841492B2 (en) 2002-06-07 2005-01-11 Honeywell International Inc. Bi-directional and multi-axial fabrics and fabric composites
JP3772207B2 (en) * 2002-06-19 2006-05-10 独立行政法人農業生物資源研究所 Biodegradable biopolymer material, production method thereof, and functional material comprising the polymer material
EP1558444B1 (en) * 2002-06-24 2016-09-21 Tufts University Silk biomaterials and methods of use thereof
GB0216060D0 (en) 2002-07-11 2002-08-21 Koninkl Philips Electronics Nv Improvements in or relating to multiple transmission channel wireless communic ation systems
JP2006504701A (en) 2002-09-30 2006-02-09 マーク・エー・バビザイェフ Method for local treatment of eye diseases, therapeutic composition and therapeutic means thereof
US7824701B2 (en) * 2002-10-18 2010-11-02 Ethicon, Inc. Biocompatible scaffold for ligament or tendon repair
WO2004041845A2 (en) 2002-11-01 2004-05-21 Trustees Of Tufts College Templated native silk smectic gels
WO2004062697A2 (en) 2003-01-07 2004-07-29 Tufts University Silk fibroin materials and use thereof
US6875787B2 (en) 2003-02-11 2005-04-05 Allergan, Inc. 10,10-dialkyl prostanoic acid derivatives as agents for lowering intraocular pressure
US20040176658A1 (en) * 2003-03-03 2004-09-09 Mcmurray Brian Warp knit fabrics useful for medical articles and methods of making same
PT2374919E (en) 2003-03-11 2013-08-26 Allergan Inc Biocompatible repair strengthening silk fabric
US7115388B2 (en) * 2003-03-14 2006-10-03 National Institute Of Agrobiological Sciences Production of functional polypeptides originating from silk protein and use thereof
EP3231846A1 (en) 2003-04-10 2017-10-18 Tufts University Concentrated aqueous silk fibroin solution and use thereof
US6840066B2 (en) 2003-04-28 2005-01-11 Hickory Springs Manufacturing Company Webbing reinforced with high-performance polymeric yarns
WO2005000483A1 (en) 2003-06-06 2005-01-06 Tufts University Method for forming inorganic coatings
US8226715B2 (en) 2003-06-30 2012-07-24 Depuy Mitek, Inc. Scaffold for connective tissue repair
US7354876B2 (en) * 2003-07-09 2008-04-08 Saint-Gobain Technical Fabrics Canada Ltd. Fabric reinforcement and cementitious boards faced with same
KR100981571B1 (en) 2003-07-26 2010-09-10 삼성전자주식회사 System and method for signal transmission and reception in mobile communication system using multiple input multiple output adaptive antenna array method
AU2004289287A1 (en) * 2003-11-10 2005-05-26 Angiotech International Ag Medical implants and fibrosis-inducing agents
US7316822B2 (en) 2003-11-26 2008-01-08 Ethicon, Inc. Conformable tissue repair implant capable of injection delivery
CA2490969C (en) 2004-01-02 2014-06-17 Her Majesty In Right Of Canada As Represented By The Minister Of Industry, Through The Communications Research Centre Canada Method for updating singular value decomposition of a transfer matrix
AU2005210630A1 (en) 2004-01-30 2005-08-18 Warsaw Orthopedic, Inc. Stacking implants for spinal fusion
US7293433B1 (en) * 2004-03-02 2007-11-13 Atex Technologies, Inc. Warp knit fabrics useful for medical articles and methods of making same
US20060030393A1 (en) 2004-03-26 2006-02-09 Atlantic City Coin & Slot Service Company, Inc. Image alignment gaming device and method
AU2005237985B2 (en) * 2004-04-20 2010-10-21 Genzyme Corporation Surgical mesh-like implant
US7682381B2 (en) * 2004-04-23 2010-03-23 Boston Scientific Scimed, Inc. Composite medical textile material and implantable devices made therefrom
US8178656B2 (en) 2004-06-11 2012-05-15 Trustees Of Tufts College Silk-based drug delivery system
US20050288797A1 (en) * 2004-06-23 2005-12-29 Warwick Mills, Inc. Controlled absorption biograft material for autologous tissue support
AU2005269864B2 (en) * 2004-07-07 2011-01-06 Cook Medical Technologies Llc Graft, stent graft and method for manufacture
US8007531B2 (en) 2004-08-06 2011-08-30 Frank Robert E Implantable prosthesis for positioning and supporting a breast implant
US7476249B2 (en) 2004-08-06 2009-01-13 Frank Robert E Implantable prosthesis for positioning and supporting a breast implant
US7429386B2 (en) 2004-09-03 2008-09-30 Allergan, Inc. Stretch mark treatment
US7102577B2 (en) 2004-09-30 2006-09-05 Motorola, Inc. Multi-antenna handheld wireless communication device
US7909867B2 (en) 2004-10-05 2011-03-22 The Board Of Trustees Of The Leland Stanford Junior University Interpenetrating polymer network hydrogel corneal prosthesis
US20060153815A1 (en) 2004-12-21 2006-07-13 Agnieszka Seyda Tissue engineering devices for the repair and regeneration of tissue
EP1833186A4 (en) 2004-12-28 2010-07-07 Fujitsu Ltd WIRELESS COMMUNICATION SYSTEM
WO2006076711A2 (en) 2005-01-14 2006-07-20 Trustees Of Tufts College Fibrous protein fusions and use thereof in the formation of advanced organic/inorganic composite materials
CA2601449A1 (en) 2005-03-22 2006-09-28 Tyco Healthcare Group, Lp Mesh implant
CA2604870A1 (en) * 2005-04-08 2006-10-19 David Philip Knight Resorbable implantable devices
EP1874222A4 (en) 2005-04-18 2012-08-22 Univ Duke THREE-DIMENSIONAL FIBER RUGS FOR TISSUE ENGINEERING
US8709023B2 (en) * 2007-07-17 2014-04-29 Poly-Med, Inc. Absorbable / biodegradable composite yarn constructs and applications thereof
EP1893174A2 (en) 2005-05-10 2008-03-05 Cytophil, Inc. Injectable hydrogels and methods of making and using same
AU2006247099A1 (en) 2005-05-18 2006-11-23 The General Hospital Corporation Dba Massachusetts General Hospital Hydrogels and hydrogel particles
US8964912B2 (en) 2005-05-31 2015-02-24 Telefonaktiebolaget Lm Ericsson (Publ) Adaptive timing recovery via generalized RAKE reception
ATE550031T1 (en) 2005-06-06 2012-04-15 Univ Georgetown COMPOSITIONS AND METHODS FOR LIPOMODELING
DE102005030614B4 (en) * 2005-06-30 2014-05-08 Biotissue Ag Cell-free graft, its use, process for its preparation, matrix thus produced with gel and process for the preparation of this matrix with gel
US8354501B2 (en) 2005-08-02 2013-01-15 Trustees Of Tufts College Methods for stepwise deposition of silk fibroin coatings
GB0516846D0 (en) 2005-08-17 2005-09-21 Knight David P Meniscal repair device
US20070071149A1 (en) 2005-09-27 2007-03-29 Linbo Li Maximum ratio combining in broadcast OFDM systems based on multiple receive antennas
US20070104692A1 (en) 2005-11-07 2007-05-10 Quijano Rodolfo C Breast tissue regeneration
US20070104693A1 (en) 2005-11-07 2007-05-10 Quijano Rodolfo C Breast augmentation system
US20100278405A1 (en) 2005-11-11 2010-11-04 Kakadiaris Ioannis A Scoring Method for Imaging-Based Detection of Vulnerable Patients
WO2007065143A2 (en) 2005-12-01 2007-06-07 Sirius Satellite Radio, Inc. Systems and methods for antenna diversity combining for satellite radio signals
US7429206B2 (en) 2006-01-18 2008-09-30 Judith Perry Upper body undergarment
JP4919464B2 (en) 2006-03-02 2012-04-18 国立大学法人大阪大学 A method for producing a three-dimensional tissue and a method for producing an extracellular matrix used therefor.
US8585753B2 (en) * 2006-03-04 2013-11-19 John James Scanlon Fibrillated biodegradable prosthesis
WO2007103442A1 (en) * 2006-03-06 2007-09-13 Board Of Supervisors Of Louisiana State Universityand Agricultural And Mechanical College Biocompatible scaffolds and adipose-derived stem cells
WO2008115188A2 (en) 2006-05-08 2008-09-25 C. R. Bard, Inc. User interface and methods for sonographic display device
EP2068766B1 (en) 2006-07-31 2011-10-19 Organogenesis, Inc. Mastopexy and breast reconstruction prostheses
WO2008118133A2 (en) 2006-09-26 2008-10-02 Trustees Of Tufts College Silk microspheres for encapsulation and controlled release
JP2010505543A (en) 2006-10-03 2010-02-25 アルレ メディカル,インコーポレイテッド Minimally invasive tissue support
US8968272B2 (en) 2006-10-06 2015-03-03 Lipocosm Llc Closed system and method for atraumatic, low pressure, continuous harvesting, processing, and grafting of lipoaspirate
US7614258B2 (en) * 2006-10-19 2009-11-10 C.R. Bard, Inc. Prosthetic repair fabric
EP2101975A2 (en) 2006-11-03 2009-09-23 Trustees of Tufts College Biopolymer sensor and method of manufacturing the same
WO2008140562A2 (en) 2006-11-03 2008-11-20 Trustees Of Tufts College Electroactive biopolymer optical and electro-optical devices and method of manufacturing the same
JP2010509645A (en) 2006-11-03 2010-03-25 トラスティーズ オブ タフツ カレッジ Biopolymer optical device having nano pattern formed thereon and method for producing the same
WO2008118211A2 (en) 2006-11-03 2008-10-02 Trustees Of Tufts College Biopolymer photonic crystals and method of manufacturing the same
US8975073B2 (en) 2006-11-21 2015-03-10 The Charles Stark Draper Laboratory, Inc. Microfluidic device comprising silk films coupled to form a microchannel
US8192760B2 (en) * 2006-12-04 2012-06-05 Abbott Cardiovascular Systems Inc. Methods and compositions for treating tissue using silk proteins
US8248970B2 (en) 2006-12-19 2012-08-21 Airgain, Inc. Optimized directional MIMO antenna system
WO2008095170A1 (en) 2007-02-01 2008-08-07 The Research Foundation Of State University Of New York A composite hydrogel
JP5643515B2 (en) * 2007-02-14 2014-12-17 シンササム,インコーポレイテッド Implants and methods for soft tissue repair
EP2129772B1 (en) 2007-02-27 2016-07-27 Trustees Of Tufts College Tissue-engineered silk organs
US8177834B2 (en) 2007-03-12 2012-05-15 Cook Medical Technologies Llc Woven fabric with shape memory element strands
JP2010522042A (en) * 2007-03-20 2010-07-01 セリカ テクノロジーズ インコーポレイティッド Tendon prosthesis and method of manufacturing the same
WO2008148071A2 (en) 2007-05-24 2008-12-04 Nidus2, Llc Injectable dermis
EP1997457B1 (en) 2007-06-01 2010-11-10 Allergan, Inc. Biological tissue growth support through induced tensile stress
US8412452B2 (en) 2007-06-05 2013-04-02 General Motors Llc System serving a remotely accessible page and method for requesting navigation related information
WO2009023615A1 (en) 2007-08-10 2009-02-19 Trustees Of Tufts College Tubular silk compositions and methods of use thereof
US7875074B2 (en) * 2007-09-19 2011-01-25 Ethicon, Inc. Naturally contoured, preformed, three dimensional mesh device for breast implant support
WO2009044540A1 (en) 2007-10-02 2009-04-09 Panasonic Corporation Portable wireless communication device
US20090181104A1 (en) 2007-12-14 2009-07-16 Gino Rigotti Breast reconstruction or augmentation using computer-modeled deposition of processed adipose tissue
WO2009086483A2 (en) 2007-12-26 2009-07-09 Gel-Del Technologies, Inc. Biocompatible protein particles, particle devices and methods thereof
US9381273B2 (en) * 2008-01-31 2016-07-05 Yissum Research Development Company Of The Hebrew University Of Jerusalem Scaffolds with oxygen carriers, and their use in tissue regeneration
CA2715288C (en) 2008-02-11 2018-06-05 Gedge Rossen Compositions and methods for implantation of adipose tissue and adipose tissue products
US8206774B2 (en) 2008-03-13 2012-06-26 Trustees Of Tufts College Diazonium salt modification of silk polymer
US8144797B2 (en) 2008-03-25 2012-03-27 Intel Mobile Communications GmbH CQI table for wireless MIMO networks
HUE043642T2 (en) 2008-07-02 2019-08-28 Allergan Inc Compositions for soft tissue filling and regeneration
US20100023029A1 (en) * 2008-07-23 2010-01-28 Bodyaesthetic Research Center, Inc. Mesh Device for Immediate Breast Construction and Uses Thereof
US20110143673A1 (en) 2008-08-06 2011-06-16 Direct-Beam Inc. Automatic positioning of diversity antenna array
US8501172B2 (en) 2008-09-26 2013-08-06 Trustees Of Tufts College pH-induced silk gels and uses thereof
US9204954B2 (en) * 2008-12-15 2015-12-08 Allergan, Inc. Knitted scaffold with diagonal yarn
US9204953B2 (en) * 2008-12-15 2015-12-08 Allergan, Inc. Biocompatible surgical scaffold with varying stretch
EP2373252B1 (en) * 2008-12-15 2015-10-14 Allergan, Inc. A prosthetic device and method of manufacturing the same
US9326840B2 (en) * 2008-12-15 2016-05-03 Allergan, Inc. Prosthetic device and method of manufacturing the same
US9308070B2 (en) * 2008-12-15 2016-04-12 Allergan, Inc. Pliable silk medical device
EP2210971A1 (en) 2009-01-26 2010-07-28 Politecnico Di Milano Silk fibroin textile structures as biomimetic prosthetics for the regeneration of tissues and ligaments
AU2010257120A1 (en) 2009-03-04 2011-10-27 Trustees Of Tufts College Silk fibroin systems for antibiotic delivery
US20100249924A1 (en) 2009-03-27 2010-09-30 Allergan, Inc. Bioerodible matrix for tissue involvement
US20110052695A1 (en) 2009-04-20 2011-03-03 Allergan, Inc. Drug delivery platforms comprising silk fibroin hydrogels and uses thereof
US20110111031A1 (en) 2009-04-20 2011-05-12 Guang-Liang Jiang Drug Delivery Platforms Comprising Silk Fibroin Hydrogels and Uses Thereof
US20110189292A1 (en) 2009-04-20 2011-08-04 Allergan, Inc. Dermal fillers comprising silk fibroin hydrogels and uses thereof
EP2421549B1 (en) 2009-04-20 2013-06-12 Allergan, Inc. Silk fibroin hydrogels and uses thereof
US9173975B2 (en) 2009-04-24 2015-11-03 Ingeneron, Inc. Reparative cell delivery via hyaluronic acid vehicles
IN2012DN00368A (en) * 2009-07-06 2015-08-21 Coloplast As
US8986377B2 (en) * 2009-07-21 2015-03-24 Lifecell Corporation Graft materials for surgical breast procedures
US8197542B2 (en) 2009-09-02 2012-06-12 Hilton Becker Self supporting implant in a human body and method for making the same without capsular contracture
US8202317B2 (en) 2009-09-02 2012-06-19 Hilton Becker Self supporting and forming breast implant and method for forming and supporting an implant in a human body
US20110106249A1 (en) * 2009-09-02 2011-05-05 Hilton Becker Self supporting and forming breast implant and method for forming and supporting an implant in a human body
US20120226352A1 (en) * 2009-09-02 2012-09-06 Hilton Becker Self supporting and forming breast implant and method for forming and supporting an implant in a human body
NZ598691A (en) * 2009-09-11 2014-05-30 Allergan Inc Prosthetic device and method of manufacturing the same
EP2483460B1 (en) * 2009-09-28 2015-09-02 Trustees Of Tufts College Method to prepare drawn silk egel fibers
CA2774917C (en) * 2009-10-05 2017-09-26 Sofradim Production Isoelastic porous mesh
US8456711B2 (en) 2009-10-30 2013-06-04 Xerox Corporation SUSAN-based corner sharpening
US9510925B2 (en) * 2010-02-02 2016-12-06 Covidien Lp Surgical meshes
US20110282365A1 (en) * 2010-05-14 2011-11-17 Ahmad Robert Hadba Surgical Implants
US20120184974A1 (en) * 2010-06-03 2012-07-19 Hilton Becker Supporting and Forming Transitional Material for Use in Supporting Prosthesis Devices, Implants and to Provide Structure in a Human Body
US20110301717A1 (en) 2010-06-03 2011-12-08 Hilton Becker Supporting and Forming Transitional Material for Use in Supporting Prosthesis Devices, Implants and to Provide Structure in a Human Body
TWI479059B (en) * 2010-08-03 2015-04-01 Global Trademarks Llc Fabric with equal modulus in multiple directions and garment fabricated
US8900571B2 (en) 2010-08-19 2014-12-02 Allergan, Inc. Compositions and soft tissue replacement methods
US8741281B2 (en) 2010-08-19 2014-06-03 Allergan, Inc. Compositions and soft tissue replacement methods
WO2012024072A1 (en) 2010-08-19 2012-02-23 Allergan, Inc. Compositions comprising adipose tissue and a pge2 analogue and their use in the treatment of a soft tissue condition
US8926963B2 (en) 2010-08-19 2015-01-06 Allergan, Inc. Compositions and soft tissue replacement methods
US8894992B2 (en) 2010-08-19 2014-11-25 Allergan, Inc. Compositions and soft tissue replacement methods
US8689362B2 (en) * 2011-02-18 2014-04-08 Patricia A. Lavin Sun protective neckwear garment
WO2014138226A1 (en) 2013-03-07 2014-09-12 Allergan, Inc. Double-cartridge syringe for mixing and dispensing adipose tissue with additive

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3448595A (en) * 1965-10-15 1969-06-10 Ludwig Povel & Co Kg Warp knitted fabric suitable for bandaging and the like
US4391106A (en) * 1978-02-22 1983-07-05 Karl Otto Braun K.G. Wound dressing
US4476697A (en) * 1980-04-21 1984-10-16 Karl Otto Braun Kg Wound dressing
US20030149464A1 (en) * 2001-07-03 2003-08-07 Scimed Life Systems, Inc. Low profile, high stretch knit prosthetic device
US20050070829A1 (en) * 2003-09-16 2005-03-31 Sofradim Production Prosthetic knit with variable properties
US9554887B2 (en) * 2011-03-16 2017-01-31 Sofradim Production Prosthesis comprising a three-dimensional and openworked knit
US9445883B2 (en) * 2011-12-29 2016-09-20 Sofradim Production Barbed prosthetic knit and hernia repair mesh made therefrom as well as process for making said prosthetic knit
US9499927B2 (en) * 2012-09-25 2016-11-22 Sofradim Production Method for producing a prosthesis for reinforcing the abdominal wall

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10660741B2 (en) * 2015-04-24 2020-05-26 Sofradim Production Prosthesis for supporting a breast structure
US11439498B2 (en) * 2015-04-24 2022-09-13 Sofradim Production Prosthesis for supporting a breast structure
US20230020617A1 (en) * 2015-04-24 2023-01-19 Sofradim Production Prosthesis for supporting a breast structure
US12161547B2 (en) * 2015-04-24 2024-12-10 Sofradim Production Prosthesis for supporting a breast structure
US20220296357A1 (en) * 2019-06-21 2022-09-22 Lazzaro Medical, LLC Airway support device
US12245929B2 (en) * 2019-06-21 2025-03-11 Lazzaro Medical, LLC Airway support device
US12064330B2 (en) 2020-04-28 2024-08-20 Covidien Lp Implantable prothesis for minimally invasive hernia repair

Also Published As

Publication number Publication date
US9308070B2 (en) 2016-04-12
US20150148823A1 (en) 2015-05-28

Similar Documents

Publication Publication Date Title
US9308070B2 (en) Pliable silk medical device
US9204953B2 (en) Biocompatible surgical scaffold with varying stretch
US9326840B2 (en) Prosthetic device and method of manufacturing the same
US20170258573A1 (en) Silk medical device for use in breast augmentation and breast reconstruction
US20140277000A1 (en) Implantable silk prosthetic device and uses thereof
US20160213456A1 (en) Silk medical device
US20120004723A1 (en) Prosthetic device and method of using in breast augmentation and/or breast reconstruction
US20120185041A1 (en) Silk medical device for use in breast augmentation and breast reconstruction
US20120022646A1 (en) Prosthetic device and method of using in breast augmentation and/or breast reconstruction
US20140088700A1 (en) Method for using a silk derived bioresorbable scaffold in breast reconstruction
AU2013383409A1 (en) Silk medical device for use in breast augmentation and breast reconstruction
US10648109B2 (en) Pliable silk medical device
US20130253646A1 (en) Silk based implantable medical devices and methods for determining suitability for use in humans
US20130245757A1 (en) Method and device for improved soft tissue surgery
US20130116785A1 (en) Silk based implantable medical devices and methods for determining suitability for use in humans
WO2016028797A1 (en) Pliable silk medical device
AU2013358983A1 (en) Silk medical device
AU2012332239A1 (en) Silk mesh and methods of use

Legal Events

Date Code Title Description
AS Assignment

Owner name: ALLERGAN, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MORTARINO, ENRICO;AKERS, JESSICA;SIGNING DATES FROM 20160319 TO 20160428;REEL/FRAME:038402/0500

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

点击 这是indexloc提供的php浏览器服务,不要输入任何密码和下载